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1 Introduction 
Equine recurrent uveitis (ERU), also known as moon blindness, recurrent iridocyclitis 
and periodic ophthalmia, affects up to 10% of the horses worldwide, and is widely 
recognized to be a complicated multifaceted disease (REBHUN 1979, SCHWINK 
1992, DEEG et al. 2002). The disease is characterized by multiple recurrent bouts of 
inflammation interrupted by phases of quiescence, which may ultimately lead to 
blindness (BARNETT 1987, DEEG et al. 2002, GERDING and GILGER 2016, 
ALLBAUGH 2017). Clinical signs vary dramatically both in number, and intensity. In 
many instances, these clinical signs remain undetected by the owner. According to 
recent studies from Canada and the Southeastern United States, approximately one 
third of the horses evaluated were bilaterally blind at their first ophthalmologic 
examination (GERDING and GILGER 2016, SANDMEYER et al. 2017). These results 
demonstrate the need for early referral in cases diagnosed with ERU, even if the 
recognizable signs are mild. Blindness may lead to a horse being retired early, and in 
some instances may require euthanasia. Both situations are coupled with emotional, 
as well as financial concerns for their owners. (REBHUN 1979, ABRAMS 1990, 
GERDING and GILGER 2016). 
Topical and/or systemic medical (immunosuppressive and anti-inflammatory) therapy 
is the foundation of any treatment protocol for horses affected with ERU. However, 
medical therapy alone cannot sufficiently control or suppress acute inflammation or 
prevent recurrent bouts of intraocular inflammation. In such instances, surgical 
intervention may be indicated (SPIESS 2010, ALLBAUGH 2017). Pars plana 
vitrectomy (PPV) and suprachoroidal cyclosporine implant (SCI) placement are both 
recognized as effective surgical treatment options for ERU (WERRY and GERHARDS 
1992, WINTERBERG and GERHARDS 1997, FRÜHAUF et al. 1998, VON BORSTEL 
et al. 2005, GILGER 2010, GILGER et al. 2010, TÖMÖRDY et al. 2010).  
More recently, minimally invasive treatment options such as intravitreal or 
suprachoroidal injections with triamcinolone (TA) have become more popular for the 
treatment of uveitis in both human and veterinary medicine (DEGENRING et al. 2003, 
BAATH et al. 2007, YI et al. 2008, GILGER et al. 2013a). These injection techniques 
are useful at suppressing acute inflammation, but are less effective at controlling the 
disease long-term or at preventing recurrences. PINARD (2005), followed by 
KLEINPETER (2014), MCMULLEN (2016), and LAUNOIS et al. (2019) first presented 
case series of horses affected with ERU that were successfully treated with low-dose 
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intravitreal Gentamicin injection (IVGI). With the exception of LAUNOIS et al. (2019), 
who used 6mg, the other case series were performed with 4mg gentamicin. The 
impetus for this treatment method was the PPV, as the irrigation solution contains 0.2-
0.4 mg/ml of Gentamicin (WERRY and GERHARDS 1992, FRÜHAUF et al. 1998, 
WOLLANKE et al. 2001, VON BORSTEL et al. 2005). This led to speculation that 
treatment with low-dose intravitreal gentamicin injection may effectively suppress 
inflammation associated with ERU (PINARD 2005). 
The anecdotal use of gentamicin is widely recognized, however, no studies evaluating 
the efficacy of this treatment method, or the potential complications associated with its 
use have been published.  
The purpose of this study was to describe the intravitreal injection technique in the 
standing, sedated horse; to describe potential peri- and post-injection complications 
associated with the procedure, and to evaluate the ability of intravitreal gentamicin to 
control ERU. 
2 LITERATURE OVERVIEW 
2.1 Etiology and pathogenesis 
2.1.1 Proposed etiologies 
The earliest speculation about potential causes of ERU surfaced during the fourth 
century AD, when Vegetius hypothesised that the moon phases are associated with 
the recurrent nature of the disease, which then lead to the term ‘moon blindness’ 
(WERRY and GERHARDS 1992). Since then, multiple authors have investigated 
whether neoplasia, trauma, infectious organisms, auto-immunity and other 
miscellaneous factors are associated with the onset of clinical signs of uveitis 
(REBHUN 1979, MILLER et al. 1987, ABRAMS et al. 1990, SCHWINK 1992, GRAHN 
et al. 2000, MAGGS 2003, BLOGG et al. 2010, BRAGA et al. 2011, PRIEST et al. 
2012).  
Although the pathophysiology is not fully understood, ERU is considered an 
autoimmune disease. Its onset and severity is also associated with environmental 
factors and or genetic predisposition (MAIR and CRISPIN 1989, DAVIDSON 1992, 
ROMEIKE et al. 1998, KALSOW and DWYER 1998, DEEG et al. 2004 and Bellone 
2017)) . Further supporting this thesis is the recurrent nature of the disease and the 
response of ERU to corticosteroids. Conversely, horses with ERU do not generally 
demonstrate a positive treatment response to antibiotics, which would be expected in 
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the case of a simple bacterial infection (MAIR and CRISPIN 1989, DAVIDSON  1992, 
ROMEIKE et al. 1998,  DEEG et al. 2008). Furthermore, ERU shows many similarities 
to autoimmune uveitis in humans in terms of the relapsing-remitting  course and the 
attack on the retina by T cells (KALSOW and DWYER 1998, WILDNER and 
KAUFMANN 2013). 
2.1.2 ERU: an immune mediated disease 
The predominant inflammatory cells in ERU affected eyes are CD4+ and T-
lymphocytes, interleukin 2 and interferon-γ. Therefore, ERU is more specifically 
considered a T-helper type 1- mediated disease (ROMEIKE et al. 1998, GILGER et al. 
1999, DEEG et al. 2002, DEEG et al. 2006). Although the precise mechanisms leading 
to initial and subsequent bouts of inflammation (i.e., recurrences) is not fully 
understood, it is commonly accepted that ERU develops following an initial bout of 
inflammation resulting in disruption of the blood ocular barrier (DEEG et al. 2002). 
Following disruption of the local immunity, CD4+ and T-lymphocytes gain access the 
eye, where they remain (ROMEIKE et al. 1998,GILGER et al. 1999,  DEEG et al. 2001, 
DEEG et al. 2002 and DEEG et al. 2006).  
The S-antigen, a photoreceptor protein found in rods and in the pineal gland and the 
Interphotoreceptor retinoid binding protein (IRBP), a large glycoprotein known to bind 
retinoids, were the first two autoantigens shown to cause an immune response (DEEG 
et al. 2001). Following identification of these antigens, IRBP was used to repeatedly 
induce uveitis in horses (DEEG et al. 2002). Thus, IRBP has been determined to be 
the major autoantigen responsible for the development of ERU (DEEG et al. 2002). 
The S-antigen, a major autoantigen in human medicine, resulted in a significantly lower 
number of uveitis cases when used experimentally to induce uveitis in horses (DEEG 
et al. 2004). Two additional retinal autoantigens have been detected more recently: 
Cellular retinaldehyde-binding protein (cRALBP), part of the rod and cone visual cycle, 
and synaptotagmin-1, a protein integral to synaptic vesicle membranes (DEEG et al. 
2006, SWADZBA et al. 2012). DEEG et al. (2002) revealed that disease severity, as 
well as the T-cell response, varied amongst the uveitis cases following experimental 
induction with IRBP. These variations were attributed to different epitopes on the 
autoantigens being recognized (DEEG et al. 2002). This phenomenon was also 
observed in horses spontaneously affected by ERU (DEEG et al. 2002). This, so-called 
‘epitope spreading’, is also thought to be responsible for the transformation of anterior 
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uveitis to a posterior uveitis, where new epitopes are exposed as a result of previous 
tissue destruction related to ocular inflammation (DEEG et al. 2001, DEEG et al. 2006). 
The specific targeting of such epitopes leads to the relapsing or recurrent nature of the 
disease (DEEG et al. 2001, DEEG et al. 2006). Despite prior identification of these 
autoantigens as well as the recognition of the consequent Type 1 T-helper cell-
associated immune response, the molecular processes responsible for  tissue 
destruction and secondary blindness are still not fully understood (GILGER and 
HOLLINGSWORTH 2016).  
DEEG et al. (2007) showed, that the retinal autoantigens remain static in number even 
after severe destruction of the retina due to ERU. With these immune response 
triggering factors still present, recurrent inflammation may still develop even in non-
visual or phthisical eyes (DEEG et al. 2007).  
 
2.2 Leptospirosis and ERU 
RIMPAU (1947) and HEUSSER (1948) first proposed an association between 
leptospirosis and ERU in the 1940s. After reports describing outbreaks of systemic 
leptospirosis consequently followed by high incidences of ERU (ROBERTS 1971), 
MORTER et al. (1969) were successful in repeating the described scenario 
experimentally. Following subcutaneous injections of blood containing Leptospira (L.) 
interrogans in a group of ponies, the herd developed signs of systemic leptospirosis, 
followed by ocular inflammation that developed weeks to months later (Morter et al. 
1969, ROBERTS 1971).  
Leptospirosis is a bacterial zoonotic disease, caused by one of more than twelve 
pathogenic species of Leptopsira (ADLER et al.2010). L. Interrogans and L. petersenii 
however, are the ones mostly associated with disease (ADLER et al.2010). The Gram 
negative spirochetes may mechanically penetrate mucous membranes or injured skin, 
thus gaining access to the vascular system where it can access many internal organs 
(MORTER et al. 1969). Most systemic infections are subclinical (HOUWERS et al. 
2011 and BÅVERUD et al. 2009). However, seroprevalence, especially in older horses, 
is high (HOUWERS et al. 2011 and BÅVERUD et al. 2009).  
Despite ERU being widely considered an immune mediated disease, Leptospirosis in 
the form of a persistent bacterial infection, is frequently considered an underlying cause 
of ERU (WOLLANKE et al. 2001, HARTSKEERL et al. 2004, BRANDES et al. 2007). 
However, neither specific antibiotic therapies nor vaccination contribute or result in 
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cessation of inflammation associated with ERU (KALSOW and DWYER 1998, 
ROHRBACH et al. 2005). Therefore, the infectious aetiology of Leptospira and 
resulting persistent bacterial infection is unlikely (KALSOW and DWYER 1998, 
ROHRBACH et al. 2005). The exact mechanism of induction of uveitis and the 
pathogenesis of how the bacteria is associated with the recurrences is not completely 
understood (GILGER et al. 2008, GILGER 2010). Increased intraocular antibodies 
compared to the serum, is indicative of local ocular antibody production (GOLDMANN 
and WITMER 1954). Recent studies support the ‘molecular mimicry’ hypothesis, with 
the immunogenic potential of certain components of the bacteria being integral to the 
development of ERU (PARMA et al. 1985, PARMA et al. 1987, PARMA et al. 1992, 
VERMA et al. 2010, VERMA et al. 2012). As such, Leptospira may account for the 
initial blood-ocular barrier disruption, which then triggers the subsequent immune 
reaction (REGAN et al. 2012). 
Several studies investigating the prevalence of Leptospira organisms or associated 
antibody titers in serum and/or ocular fluids have been undertaken (BARNETT 1987, 
HALLIWELL et al. 1985, DWYER et al.1995, FABER et al. 2000, WOLLANKE et al. 
2001, HARTSKEERL et al. 2004, GILGER et al. 2008, LOWE 2010, VANBorstel et al. 
2010, MALALANA et al. 2017 and SAUVAGE et al. 2018). WOLLANKE et al. (2001) 
isolated L. interrogans from vitreous samples of 52% (120/229) of the horses 
undergoing pars plana vitrectomy as treatment for ERU in Southern Germany. Serum 
antibody titers ≥1:400 against one or more serovars of L. interrogans were found in 
44% (106/241) of the horses and in the vitreous of 80% (194/242) of the horses, 
respectively (WOLLANKE et al. 2001). The most commonly isolated serovar was L. 
grippothyphosa (WOLLANKE et al. 2001).  HARTSKEERL et al. (2004) isolated 
Leptospira in 32.2% (199/618) of the vitreous- and aqueous humor (AH) samples in 
their study. There was no distinction between the two ocular locations. In the studies 
carried out in North America, L. pomona was the most commonly isolated serovar 
HALLIWELL et al. (1985), DWYER et al. (1995) and FABER et al. (2000).  FABER et 
al. (2000) used polymerase chain reaction (PCR) (21/30 horses, 70%) and culture 
(6/27 horses, 22.2%) to detect Leptospira in the aqueous humor and 
microagglutination test (MAT) for the evaluation of Leptospira antibody titers (positive 
titer ≥1:100) in the serum (24/28 horses, 85.7%).  In contrast to the high prevalence of 
Leptospira in the previously described studies, GILGER et al. (2008) failed to detect 
any bacterial DNA in samples collected from ERU affected horses from the 
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Southeastern United States. Fifty-seven percent (57/100) of the vitreous humor 
samples had antibody titers against Leptospira VAN BORSTEL et al. (2010). A 
definition concerning the cut-off for a positive titer was not given.  DNA was detected 
via PCR in 40% (40/100) of the samples from horses from Northern Germany VAN 
BORSTEL et al. (2010). The most prevalent serovar isolated in this study was L. 
grippotyphosa VAN BORSTEL et al. (2010). SAUVAGE et al. (2018) isolated 
Leptospira DNA in 30.3% (20/66) of the aqueous humor and/or vitreous samples via 
PCR, however, MAT was not performed.  
In order to determine if local, intraocular antibodies against Leptospira are being 
produced it is recommended to calculate the ratio between the aqueous humor 
antibody titer and the serum antibody titer (GOLDMANN and WITMER 1954, GILGER 
2008). The result, also known as the Leptospira-status of the eye, or the C-value, is 
considered positive, when the ratio is at least four (i.e.,  the aqueous humor antibody 
titer is at least four-fold higher than the antibody titer found in the serum) (GOLDMANN 
and WITMER 1954, GILGER 2008). The Leptospira-status is considered suspicious in 
the event that the value is at least one, but less than four (GILGER et al. 2008). A C-
value less than one is considered negative (GILGER et al. 2008).  GROOT-MINJES et 
al. (2006) determined that PCR results are an unreliable method of detecting the 
presence of Leptospira, as nearly 50% of the Leptospira-associated uveitis cases 
evaluated would have been missed using PCR alone.  
Horses from the United Kingdom (UK) are not only less likely to be diagnosed with 
ERU, Leptospira also plays only a minor role in that geographic area (BARNETT 1987, 
LOWE 2010). MALALANA et al. (2017) recently investigated the role of Leptospira in 
the UK and found that only two of 30 ERU affected eyes had at least a four-fold 
increase of Leptospira aqueuous humor antibody titers when comparing aqueous 
humor to serum antibody titers. The most commonly isolated serovars in this study 
were L. bratislava followed by L. autumnalis MALALANA et al. (2017).   
 
2.2.1 Genetic predisposition for ERU 
It is suspected that genetics play an important role in the development and severity of 
ERU. Early speculations were triggered, when ERU rates decreased tremendously in 
the UK after stallions with cataracts were excluded from breeding (LORBEER 1940). 
By confirming that the MHC (major histocompatibility complex) gene region contributes 
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to a horse’s risk of developing ERU, DEEG et al. (2004) provided evidence linking 
genetics and ERU.  
Studies investigating the genetic predisposition of certain breeds, have shown that 
Appaloosas are eight times more likely to develop uveitis, and have a 3.8 times higher 
susceptibility to become blind from ERU than non-Appaloosas (DWYER et al. 1995, 
ANGELOS et al. 2009). Appaloosas are bred with a selection for the leopard complex 
spotting locus (LP) (FRITZ et al. 2014). The LP is incompletely dominant and most 
Appaloosas carry either a homozygous or heterozygous form (SPONENBERG et al. 
2017). The LP is responsible for the breed’s typical appearance with a distinct white 
pattern, which may have oval, pigmented spots within that white area (SPONENBERG 
et al. 2017).  Homozygous horses for LP have the highest risk of developing ERU, 
thus, coat color may be used as a means to identify horses with the greatest risk 
(FRITZ et al. 2014). In addition to the LP-associated allele, two additional alleles on 
two different microsatellites, have been associated with an increased risk of ERU 
(FRITZ et al. 2014). However, the LP test is currently the only routine genetic test 
available (BELLONE 2017).  
KUHLBROCK et al. (2013) carried out a genome-wide association study to identify 
potential risk loci conferring to ERU in German warmblood horses. The study revealed 
that genes Interleukin-17A and Interleukin-17F appeared to play an important role in 
the development of ERU, but further studies are required to test for influencing factors 
among genetic variants. 
 
2.3 Definition of ERU 
2.3.1 Classification and syndromes  
Historically, ERU has been divided into the following syndromes: Classic ERU, 
insidious ERU, and posterior ERU (GILGER and MICHAU 2004). Classic ERU is 
characterized by inflammation of the uvea in association with other parts of the globe 
including the cornea, anterior chamber, lens, vitreous and retina, but which interrupted 
by variable phases of quiescence. The severity of the active bouts of inflammation tend 
to increase over time (REBHUN 1979, ABRAMS et al.1990, SCHWINK 1992). 
Insidious uveitis is difficult for the owner to recognize, as horses do not tend to show 
obvious signs of discomfort even in the face of severe intraocular inflammation 
(GILGER 2010, GILGER et al. 2004). A persistent low-grade inflammation is typical for 
this syndrome (GILGER 2010, GILGER et al. 2004). Appaloosas and draught breeds 
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tend to be overrepresented in the insidious ERU category (GILGER 2010, GILGER et 
all. 2004). Posterior uveitis mainly affects the posterior segment and is generally 
confined to the vitreous, retina and choroid (Schwink 1992). Therefore, this syndrome, 
which mostly affects Warmbloods, draught breeds and European horses, can likewise 
cause tremendous damage to the eye before being noticed by the owner (GILGER 
2010, ALLBAUGH 2017). 
 
2.3.2 Clinical symptoms 
As the name suggests, ERU is characterized by recurrent inflammation of the uvea, 
which may involve the iris, the ciliary body or the choroid individually, or collectively 
(REBHUN 1979, MILLER and WHITLEY 1987, ABRAMS and BROOKS 1990, 
SCHWINK 1992, DAVIDSON 1992, GILGER and MICHAU 2004). Clinical signs may 
vary significantly in both quantity and intensity, and can include any combination of the 
following: photophobia, blepharospasm, enophthalmos, hypotony, conjunctival or 
episcleral vascular congestion, corneal edema, corneal vascularization, aqueous flare, 
hypopyon, hyphema, miosis, iris edema or congestion, , synechiae (anterior or 
posterior), cataract, vitreal traction bands, vitreal haze, depigmentation of the 
peripapillary region in a focal or alar pattern, loss of peripapillary fundic detail, retinal 
vascular congestion or edema, retinal cellular infiltrate (REBHUN 1979, MILLER and 
WHITLEY 1987, ABRAMS and BROOKS 1990, SCHWINK 1992, DAVIDSON 1992, 
GILGER and MICHAU 2004).  
Signs commonly associated with ERU may be identified in association with other 
diseases such as secondary glaucoma, immune mediated keratitis (IMMK) or 
conjunctivitis, conjunctival foreign bodies, corneal ulcers or stromal abscesses 
(ALLBAUGH 2017). Establishing a correct and accurate diagnosis may present a 
significant challenge. This is especially challenging in other diseases with a persistent 
or recurrent pattern of inflammation, such as heterochromic iridocyclitis and keratitis 
(PINTO et al. 2014) and IMMK (REBHUN 1979, GILGER 2010).  
 
2.4  Diagnostic testing for ERU (Leptospira) 
2.4.1  Sample collection (aqueous humor, vitreous humor, serum) 
Aqueous humor can be aspirated from the anterior chamber via aqueous paracentesis. 
This can be performed under general anaesthesia or under standing sedation with 
topical anaesthesia (FEATHERSTONE et al. 2013). It is crucial to aseptically prepare 
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the conjunctival fornices with 1.0 mL of dilute baby shampoo solution, 1.0 mL of a 1% 
dilute iodine solution, followed by 1.0 mL of balanced salt solution or eyewash prior to 
aqueous paracentesis (BROOKS et al. 2017.). Globe exposure may be facilitated 
using an eyelid retractor (FISCHER et al. 2019). The injection site of the left and right 
eyes are at the 1:00 and 11:00 o’ clock position, respectively. A 27-30 gauge needle 
syringe combination or an insulin syringe with a swaged-on needle can be used to 
slowly aspirate 0.2-1.0 mL of aqueous humor (FEATHERSTONE et al. 2013, 
FISCHER et al.  2019). Historically, vitreous samples have mostly been collected 
during pars plana vitrectomy (WOLLANKE et al. 2001, HARTSKEERL et al. 2004, 
BRANDES et al. 2007, VON BORSTEL et al. 2010, BAAKE et al.2016). The injection 
site for vitreous paracentesis is located 10-12 mm from the dorsolateral limbus, in order 
to facilitate the needle placement through the pars plana and to placement of the 
needle through the sensory retina (MILLER et al. 2001). A 23- to 25 gauge needle is 
inserted through the sclera with the needle tip directed vitread towards the optic nerve 
(MILLER et al. 2001).  
Serum can be obtained via routine blood draw from the jugular vein.  
 
2.4.2  Methodology 
Leptospira can be detected indirectly via microagglutionation test (MAT) or directly via 
polymerase chain reaction (PCR) or culture (MOCHMANN 1963). Concerning the 
direct methods, a positive test result is considered proof of Leptospira’s presence, 
whereas a negative test result may be a false negative (MOCHMANN 1963). Taking a 
sample during a period of quiescence or failure to aspirate an adequate number of 
organisms may lead to a negative test result (MOCHMANN 1963). 
 
2.4.2.1 Microagglution test (MAT) 
With its high sensitivity and specificity, MAT is an effective way of testing samples for 
Leptospira (COLE 1973, BABUDIERI 1961, FAINE 1982). The samples are incubated 
with a live antigen and diluted up until 50% of the Leptospira are being agglutinated 
(GUSSENHOVEN et al. 1997, FAINE et al. 1999, LEVETT 2001). A titer of 1:100 or 
higher is considered positive, depending on the laboratory (AHMAD et al. 2005, OIE 
2008). Comparing the antibody production of an intraocular compartment (aqueous 
humor/vitreous humor) to that of the serum, helps to detect the presence of and 
determine the severity of the local antibody production in the eye. A 4-fold increase, 
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when comparing the two localisations is considered positive (GOLDMANN and 
WITMER  2010). 
 
2.4.2.2 Polymerase chain reaction (PCR) 
PCR is a direct method to amplify specific DNA sequences of Leptospira with a high 
sensitivity and specificity (SMITH 1994, WIESNER e al. 1994). Another positive aspect 
is the relatively small amount of fluid (50-100 µL) that is needed to perform a PCR 
(SMITH 1994). It is not possible to determine the specific Leptospira serovar via PCR 
(AHMAD et al. 1995). 
 
2.4.2.3 Cultures 
Liquid or semi liquid culture media can be used for culture of Leptospira (BABUDIERI 
1961). Currently, the most commonly used medium is EMJH base and enrichment 
medium, also referred to as bovine serum albumin-Twee 80 (LEVETT 2016). Cultures 
must be consistently evaluated for at least 16 weeks before they may be considered 
negative (ELLIS 1986). 
 
2.5 Treatment of ERU 
2.5.1  Medical management  
The goals of treatment for ERU are the preservation of vision and the control of pain 
associated with intraocular inflammation  (REBHUN 1979, MILLER and WHITLEY 
1987, SCHWINK 1992, WERRY and GERHARDS 1992). Traditional medical 
management of ERU consists of topical and systemic medications to suppress and 
control inflammation and to facilitate pain management (non-steroidal anti-
inflammatory drugs, corticosteroids, and mydriatics)(REBHUN 1979, ABRAMS and 
BROOKS 1990, WERRY and GERHARDS 1992). Topical administration of 
medications may not always be feasible. Horses that are experiencing significant 
ocular pain may be non-compliant, and present unique treatment challenges (YI et al. 
2008). Each sequential bout of inflammation compounds the effects of the disease on 
the horse, which may ultimately lead to blindness (SPIESS 2010, GERDING et al. 
2016, MCMULLEN et al.2017, SANDMEYER et al.2017). Therefore, not only is it 
crucial to suppress active inflammation, but also to prevent recurrent inflammation 
(GILGER et al. 2004, MCMULLEN et al. 2017). While medical management may be 
very effective at suppressing and controlling acute inflammation, it cannot effectively 
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prevent recurrent bouts of inflammation (GILGER et al. 2004, GERDING et al. 2016, 
MCMULLEN et al. 2017).  For the long-term preservation of vision, early surgical 
intervention, if indicated, is essential (SPIESS 2010, ALLBAUGH 2017, MCMULLEN 
et al. 2017).  
 
2.5.2 Intravitreal and suprachoroidal injections 
2.5.2.1 Intravitreal rapamycin injections 
Rapamycin is a carbocyclic lactone-lactam macrolide antibiotic (TREPANIER et al. 
1998). Unlike tacrolimus and cyclosporine, rapamycin is a non-calcineurin inhibitor and 
promotes the expansion of T regulatory cells and inhibits the differentiation of 
pathogenic T helper 17 cells (KOPF et al. 2007). A clinical study published by 
DOUGLAS et al. (2008) showed that therapeutic concentrations of rapamycin were 
detectable for at least three weeks (the duration of the study) in the vitreous of normal 
horses following intravitreal injection. No intraocular toxicity was observed throughout 
the duration of the study (DOUGLAS et al. 2008). Studies on horses with naturally 
occurring ERU are required to evaluate the treatment outcome and complication rate 
associated with intravitreal rapamycin injections.  
 
2.5.2.2 Intravitreal triamcinolone injections 
Intravitreal injections with triamcinolone acetonide (IVTA) have been utilized in both 
human and veterinary medicine for the treatment of uveitis (DEGENRING et al. 2003, 
BAATH et al. 2007, YI et al. 2008). Triamcinolone acetonide, injected at a dosage of 
between 4 to 20 mg, lasts approximately 4 to 9 month in the vitreous of human patients 
(JONAS et al. 2006). A retrospective study in human medicine graded the IVTA as an 
exceptionally safe treatment method (BAATH et al. 2007). Caution is required in 
patients with a history of glaucoma, as an increase in intraocular pressure (IOP) is the 
most common complication associated with IVTA injections in people (BAATH et al. 
2007). An additional glaucoma medication was required in 58.8% of the patients with 
pre-existing glaucoma (BAATH et al. 2007). In a study evaluating the ocular distribution 
and toxicity of triamcinolone acetonide following intravitreal injection in normal equine 
eyes, there was no report on the effect of TA on IOP (YI et al. 2008). The only 
complication reported following IVTA in normal equine eyes treated with 10, 20 or 40 
mg of TA, was transient corneal edema, which was observed regardless of the drug 
11
concentration used (YI et al. 2008). However,  caution should be utilized when using 
IVTA in areas where fungal keratitis is overrepresented, as the high AH levels of TA in 
equine eyes following IVTA predispose these horses to fungal keratitis (YI et al. 2008). 
Following IVTA, triamcinolone acetonide cannot be removed and was associated with 
elevated ocular TA levels for the 21 day study duration (YI et al. 2008).  
Three eyes from the control group and one eye from the treatment group developed 
endophthalmitis associated with bacterial infection, which emphasizes the need for 
proper aseptic preparation before any injection is performed (YI et al. 2008). 
 
2.5.2.3 Suprachoroidal triamcinolone injections 
The potential for complications associated with increased intraocular levels of TA, 
including a predisposition to fungal keratitis following IVTA can be largely avoided by 
injecting TA into the suprachoroidal space using custom-made micro needles (GILGER 
et al. 2013). A porcine model showed that suprachoroidal injection of TA (0.2mg and 
2.0mg) had the same effect as IVTA (2.0mg) on controlling posterior uveitis (GILGER 
et al. 2013).  Additionally, there were no adverse side effects noted, nor were any toxic 
reactions evident following suprachoroidal injections of TA (GILGER et al. 2013).  
 
2.5.2.4 Low-dose intravitreal gentamicin injections 
Gentamicin is a bactericidal aminoglycoside antibiotic that has been routinely added to  
the irrigation solution (0.2 – 0.4 mg/ml) during pars plana vitrectomy (WERRY and 
GERHARDS 1992, FRÜHAUF et al. 1998, VON BORSTEL et al. 2005, WOLLANKE 
et al. 2001). Based on this use, and the desire to avoid invasive intraocular surgery, it 
was utilized as a sole treatment option by injecting directly into the vitreous of horses 
with ERU (PINARD 2005). PINARD (2005) presented the first results from a group of 
horses treated with low-dose (4mg) IVGI. Eighteen eyes from ten horses were treated 
with IVGI under general anaesthesia (PINARD 2005).  Seventeen of the 18 eyes 
treated with IVGI remained free from recurrences (PINARD 2005). KLEINPETER et al. 
(2014) presented data from 60 eyes treated with IVGI under general anaesthesia. 
Ninety-three percent of the eyes did not develop recurrences, but 11/60 eyes 
developed a cataract following IVGI (KLEINPETER et al. 2014). MCMULLEN (2015) 
presented the first case series of horses treated via IVGI under standing sedation. 
Thirty-three eyes were treated with 4mg IVGI and showed signs of improvement within 
24 to 48 hours after the injection (MCMULLEN 2015). FISCHER et al. (2019) presented 
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data from 86 horses treated with IVGI (4mg) under standing sedation. A total of 88.1% 
of the horses remained free from persistent or recurrent bouts of inflammation following 
IVGI. Cataract formation was seen in 8.5% and retinal degeneration in 5.1% of the 
cases (FISCHER et al. 2019).  Kleinpeter et al. (2019) later published the data from 
his presentation in 2014, with sixty-one treated eyes between the years of 2006 - 2013. 
Ninety-one point eight percent of these eyes had no further recurrences. Eighteen of 
the 61 eyes became blind, which was mostly due to cataract progression of a pre-
existing cataract prior to IVGI. KLEINPETER et al. (2019) concluded that IVGI has a 
low complication rate and serves as a viable alternative to the PPV, a surgery widely 
utilized throughout Germany. LAUNOIS et al. (2019) presented a case series of 71 
horses that were treated with 6mg IVGI. According to a telephone enquiry, 70/71 
horses did not have another observable bout of inflammation within six month of the 
IVGI (LAUNOIS et al. 2019). 
 
2.5.3  Surgical procedures 
2.5.3.1 Suprachoroidal cyclosporine implants 
Surgical intervention via cyclosporine (CsA) suprachoroidal implants (CSI) for the 
treatment of ERU was first published by GILGER et al. (2006). The mechanism of 
action of CSI is to inhibit calcineurin and therefore block Interleukin-2 transcription, 
which subsequently leads to an impaired proliferation of activated T-helper and T-
cytotoxic cells (KERMANI-ARAB et al. 1985, KAY 1989, HOLLÄNDER et al. 1994). 
Horses with ERU that received a CSI had a significantly decreased frequency of uveitis 
flare-ups following surgery than before the implantation (GILGER et al. 2006). Previous 
cyclosporine A implant devices to treat ERU were designed to be placed directly into 
the vitreous (GILGER et al. 2000). The intravitreal drug levels of cyclosporine A were 
determined to be too low to suppress inflammation and further development led to the 
suprachoroidal implants that are currently utilized (GILGER et al. 2000, GILGER et al. 
2006).  
Mild temporary conjunctival hyperaemia is a reported complication associated with SCI 
placement (GILGER et al. 2006). Eleven percent of the horses in a study evaluating 
the long-term results following  placement of a CSI were found to be blind due to 
uncontrolled uveitis or glaucoma, cataract progression or retinal detachment (GILGER 
et al. 2010). Vision was preserved following placement of a CSI  in nearly 80% of the 
eyes with a minimum mean follow-up time of 28 month (GILGER et al. 2010). The 
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authors of this study recommend replacing the CSI prior to 48 months following 
implantation, as both clinical and in-vitro observations suggest a depletion of drug 
release from the device around that time (GILGER et al. 2006, GILGER et al. 2010). 
There are specific challenges associated with CSI, especially in Europe, that one must 
consider when developing a treatment plan for horses diagnosed with ERU. First, the 
CSI are neither commercially available, nor are they FDA approved. Their import to 
any European country is thus forbidden, with the exception of academic institutions 
that have been granted explicit permission to import the CSI within the framework of 
an ongoing and existing research project (MCMULLEN et al. 2017). Second, horses 
with uveitis that cannot be controlled with conventional medical therapy are considered 
poor surgical candidates for the CSI, and alternative treatment options should be 
considered (GILGER and MICHAU 2004, GILGER et al. 2010, ALLBAUGH 2017, 
MCMULLEN et al. 2017).  
 
2.5.3.2 Pars plana vitrectomy 
The first surgical intervention used to treat ERU, PPV was adapted from human 
ophthalmology in the late 1980’s (WERRY and HONEGGER 1987). The goal of the 
PPV is to remove the central vitreous body in order to remove vitreal opacifications 
that may be interfering with vision, as well as to remove any inflammatory cells 
sequestered within the vitreous (WERRY and Gerhards 1992). WERRY and 
GERHARDS (1992) first published a case series of horses affected with ERU treated 
via PPV. According to communications with the primary veterinarians, the 9/10 horses 
that underwent PPV and were released from the clinic did not experience any further 
recurrent bouts of inflammation (WERRY and GERHARDS 1992). Observed 
complications associated with the PPV were postsurgical pain, fibrin accumulation in 
the anterior chamber, vitreal hemorrhage, and one horse was euthanized due to 
irreversible blindness resulting from a complete retinal detachment (WERRY and 
GERHARDS 1992). WINTERBERG and GERHARDS (1997) evaluated 43 eyes from 
horses undergoing vitrectomy for treatment of ERU. Despite only 1/43 eyes 
experiencing further bouts of recurrent inflammation, 12/43 eyes were non-visual 
during reevaluation and 14/43 eyes demonstrated deteriorated visual status 
(WINTERBERG and GERHARDS 1997). Vision loss or decreased vision was 
contributed to cataract formation or progression, complete or partial retinal 
detachment, vitreal opacification, secondary glaucoma and phthisis bulbi 
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(WINTERBERG and GERHARDS 1997).  In another study, 38 eyes from 35 horses 
undergoing PPV for ERU, from the University of Hannover, Germany, were evaluated 
postoperatively (FRÜHAUF et al. 1998). Horses with phthisis bulbi, secondary 
glaucoma or retinal detachment were excluded from the study population, and the 
surgery was only performed during a period of quiescence (FRÜHAUF et al. 1998). 
Long-term follow up examinations were carried out by the authors in 27/38 eyes, with 
the remainder of the follow-up data communicated through the owners or local 
veterinarians (FRÜHAUF et al. 1998). No further recurrences were detected in 85% of 
the eyes, however, vision was compromised in 15% of the eyes due to recurrent 
inflammation or cataract progression (FRÜHAUF et al. 1998). Intraoperative 
complications or complications observed immediately after surgery, were 
intraoperative vitreal or intraocular hemorrhage, vitreal hemorrhage post-anesthetic 
recovery, slight subretinal hemorrhage and transient hypopyon (FRÜHAUF et al. 
1998). TÖMÖRDY et al. (2010) investigated the outcome of PPV with regard to the 
Leptospira status of the eye and concluded that PPV is not associated with a  high rate 
of success in eyes without  intraocular antibodies against Leptospira, as 85.7% of the 
cases with negative aqueous humor MAT results went on to develop further bouts of 
inflammation postoperatively (TÖMÖRDY et al. 2010) . The rate of recurrence in eyes 
testing positive for antibodies against Leptospira however was only 17.5%, this 
difference was statistically significant (TÖMÖRDY et al. 2010).  
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Intravitreal injection of low-dose
gentamicin for the treatment of recurrent
or persistent uveitis in horses: Preliminary
results.
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Abstract
Background: Despite appropriate medical therapy, many horses with equine recurrent uveitis continue to suffer
from recurrent bouts of inflammation. Surgical intervention via the pars plana vitrectomy or suprachoroidal
cyclosporine implant placement may control and/or prevent recurrences, however, these procedures may be
contraindicated, unavailable, or declined by an owner. Thus, an effective adjunctive treatment option may
help to improve the clinical outcomes in those situations. There are several anecdotal reports on the use
of intravitreal gentamicin injections, but to date, no data evaluating the complication rate and/or treatment
effect following this treatment have been published. Thus, the aim of this prospective study was to describe
the intravitreal gentamicin injection technique, describe the associated peri-injection (within 24 h) and post-
injection (30 to 780 days) complications, and to report the effects of the injection on the clinical signs of
uveitis. Additionally, evaluation of the systemic and ocular Leptospira-status, and its effect on the treatment
outcome was performed. A total of 86 horses of various ages, breeds, and gender presenting with recurrent
or persistent uveitis were treated via intravitreal injection of 4 mg of undiluted gentamicin (0.04 ml, Genta 100,
100 mg/ml in 35 horses) or preservative-free gentamicin (0.05 ml, 80 mg/ml in 52 horses) under sedation and
local anesthesia. All 86 horses were observed for immediate peri-injection and post-injection complications.
Response to therapy was evaluated in 59 of the 86 horses (follow-up: 30 to 780 days).
Results: Peri-injection complications consisted of subconjunctival (26/86; 30.2%) or intracameral hemorrhage
(4/86; 4.7%); both of which completely resolved within 5 days. Post-injection complications consisted of
cataract formation/maturation (5/59 horses, 8.5%) and diffuse retinal degeneration (3/59 eyes 5.1%). The
majority of horses 52/59 (88.1%) with a minimum follow-up period of 30 days were controlled (absence
of recurrent or persistent inflammation) at their last recheck examination. Recurrent inflammation was
documented in 5/59 (8.5%) horses and persistent inflammation was diagnosed in 2/59 (3.4%) horses.
Conclusions: Intravitreal injection of low-dose gentamicin shows promise at controlling different types and
stages of uveitis. The ability of intravitreal injections of low-dose gentamicin (4 mg) to control persistent
and recurrent inflammation warrants further investigation.
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AH) and leptospiral DNA (AH) and their effect on the
treatment outcome.
Results
Horses
A total of 86 horses with a mean follow-up period of
165.9 ± 190.3 days (range: 1 to 780 days) were included
in the present study. The mean age was 11.6 ± 5.5 years
(range: 2 to 28 years). Gender, breed and coat color dis-
tribution can be found in Table 1. Twenty-nine horses
were treated bilaterally, resulting in one eye being ran-
domly selected for evaluation.
Fifty-nine of the 86 eyes had a minimum follow-up
period of 30 days (range: 30 to 780 days) and comprised
the group undergoing statistical evaluation of
post-injection complications and clinical treatment out-
come. Fifty-two of 59 eyes (88.1%) were controlled (non--
recurrence/persistence, independent of complications)
after the IVGI, and despite the discontinuation of topical
and medical therapy. Overall, 5/59 eyes (8.5%) presented
with recurrent and 2/59 eyes (3.4%) presented with per-
sistent inflammation during follow-up examination. The
follow-up data and corresponding results of positive out-
come are listed in Table 2. Category distributions are listed
in Fig. 1, Tables 3 and 4.
Leptospira status
Aqueous humor was obtained from 79/86 (91.9%) eyes
and serum from 80/86 (93%) horses. Table 5 shows the
calculated c-values for each individual Leptospira serovar
and the combined results are documented in Table 6.
Leptospira PCR was performed on 79 eyes, 23 of which
were positive 23/79 (29.1%). Based on our inclusion
criteria and calculation of c-values for each eye 50/79
eyes (63.3%) were classified as Leptospira negative, 13/79
eyes (16.5%) were classified as Leptospira suspicious and
the remaining 16/79 eyes (20.3%) were classified as Lep-
tospira positive.
Peri-injection complications
Subconjunctival and intracameral hemorrhage (due to
the aqueous paracentesis) were seen in 26/86 (30.2%)
and 4/86 (4.7%) of the eyes, respectively, but were com-
pletely resolved within 5 days.
Post-injection complications
Fifty-nine of 86 eyes had a minimum follow-up period of
30 days (30–780 days) and were evaluated for the pres-
ence of post-injection complications. Cataract forma-
tion/maturation was observed in 5/59 (8.5%) eyes, and
retinal degeneration was seen in 3/59 eyes (5.1%). Four
of the five cataracts that developed post-injection were
identified in horses that received gentamicin with preser-
vatives. Cataract progression/maturation occurred within
Background
Equine recurrent uveitis (ERU) is widely recognized as 
an immune-mediated disease characterized either by 
recurrent bouts of ocular inflammation separated by 
variable periods of quiescence (lack of detectable ocular 
signs associated with active inflammation) or low-grade, 
persistent inflammation [1–3]. The cornerstone of treat-
ment for ERU consists of local immunosuppression or 
immune-modulation in conjunction with systemic 
anti-inflammatory treatment [4–7].
In addition to medical therapy, there are two widely 
utilized surgical procedures, cyclosporine suprachoroidal 
implants (CSI) and pars plana vitrectomy (PPV), that are 
routinely performed to treat horses with ERU [8–14]. 
Implantation of a CSI has been proven to be an effective 
means of controlling uveitis in horses responsive to prior 
medical therapy [3, 8, 13, 15]. However, because their 
legal importation into Europe is restricted to academic 
institutions for specific use in ongoing research, the use 
of CSI is severely limited on this continent. A more 
commonly performed surgery in Europe (especially 
Germany) is the PPV [9, 10, 14, 16]. Initially, PPV was 
utilized to treat all forms of ERU, but recently published 
data suggests that it is most effective in horses with con-
firmed leptospiral etiology [14].
Two recent studies demonstrated the relative inability 
of medical therapy to adequately control and prevent 
long-term complications and blindness in a large pro-
portion of horses evaluated, highlighting the importance 
of additional treatment modalities [17, 18]. Intravitreal 
injections with triamcinolone acetonide or rapamycin 
have been successfully utilized in the management of re-
current uveitis in humans, as well as in small groups of 
horses [19–23]. However, the rate of complications and 
lack of long-term control of ERU, has limited their use 
in equine ophthalmology. Gentamicin (0.2–0.4 mg/ml), a 
bactericidal aminoglycoside antibiotic, has been rou-
tinely added to the PPV irrigation solution since the sur-
gery’s introduction in the early 1990s [9–11, 24]. This 
led to speculation that low-dose intravitreal gentamicin 
(4 mg) injections (IVGI) alone could serve as an alterna-
tive treatment for ERU, and initial results were presented 
by Pinard, et al. in 2005 [25]. Despite widespread anec-
dotal use, there are no published studies evaluating the 
efficacy of this treatment or establishing the risk of com-
plications following IVGI.
The purpose of this prospective study was to describe 
the intravitreal gentamicin injection technique, to iden-
tify any peri-injection (within 24 h) and/or post-injection 
(30 to 780 days follow-up) complications associated with 
the IVGI and to evaluate the clinical outcome in horses 
with ERU, following a single 4 mg IVGI. Additionally, 
aqueous humor (AH) and serum (S) samples were evalu-
ated for the presence of leptospiral antibody titers (S and
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one week (1/5, 20%), within one year (3/5, 60%), and
later than one year post-IVGI (1/5, 20%). All eyes, that
developed mature cataracts, presented with cataracts of
different stages before IVGI (Fig. 2). Retinal degener-
ation, not associated with obvious visual deficits (as
assessed via menace response), was identified in 3/59
(5.1%) eyes (Fig. 3), and was consistently identified as a
horizontal, geographic area (between one and three disc
diameters in size) of diffuse tapetal hyperreflectivity
superior to the optic nerve head. This complication was
identified in a single eye at each of the following time
points: Within 30 days, between 30 and 60 days, and
between 90 and 122 days following IVGI, respectively.
None of these eyes showed signs of retinal degeneration
prior to IVGI.
Statistical evaluation of factors influencing treatment
outcomes and complication rates
Variables with a significant effect on treatment outcome
or on the development of long-term complications, are
presented in Table 7. A significant correlation was iden-
tified between the Appaloosa breed and recurrence of
inflammation (P < 0.001). In each of these horses, uveitis
remained controlled in the early stages of follow-up.
However, over time, aqueous flare was detectable in all
three eyes. Leopard-patterned horses were more likely to
develop recurrent inflammation than horses with other
coat colors (P = 0.049). None of the eyes, that developed
retinal degeneration, had detectable aqueous flare
pre-IVGI (P = 0.046). The presence of subconjunctival or
intracameral hemorrhage post-IVGI did not have a
significant influence on either the control of the uveitis,
or the development of long term-complications. Neither
the clinical diagnosis, nor the additional categories utilized
to subjectively grade equine uveitis in the present study
had any influence on the control of the uveitis or the de-
velopment of post-injection complications. The Leptospira
antibody status of the eye (positive, suspicious, or negative
C-value) and aqueous humor Leptospira PCR results did
not have a significant influence on the development of
long-term complications. There was a significant influence
on the development of persistent inflammation in one eye
with multiple positive C-values ≥4 (C-value of 8 for L.
pomona and C-Value of 4 for L. grippotyphosa)
(P = 0.015), multiple aqueous humor titers ≥1:400 (aqueous
humor titer for L. Pomona 1:800 and for L. grippoty-
phosa 1:1600) (P = 0.013) and one positive serum
titer ≥1:400 (serum titer for L. grippotyphosa 1:400)
(P = 0.047). Although not significant, 4/5 (80%)
mature cataracts developed following IVGI injection
with gentamicin containing preservatives (Genta100).
Discussion
Many horses with ERU require additional treatment mo-
dalities in addition to medical therapy. Both the PPV
and CSI placement are commonly performed in Europe
and the USA, respectively [8, 15, 16, 26]. Although CSI
placement can effectively suppress intraocular
Table 1 Gender, breed and coat color distribution of the horses
(n = 86) that had undergone IVGI between January 2013 – June
2016
Gender n = 86 Geldings 49 (57%)
Mares 31 (36%)
Stallions 6 (7%)
Breed n = 86 Warmblood 38 (44.2%)
Quarter Horse; Paint Horse 9 (10.5%)
Icelandic Horse 6 (7.0%)
Pony 6 (7.0%)
Heavy Warmblood 5 (5.8%)
Standardbred Trotter 5 (5.8%)
Haflinger 5 (5.8%)
Appaloosa 4 (4.7%)
Spanish 3 (3.5%)
Knabstrupper 3 (3.5%)
Thoroughbred 2 (2.3%)
Coat Color Distribution
n = 86
Bay 36 (41.9%)
Chestnut 16 (18.9%)
Gray 11 (12.8%)
Leopard-patterned 11 (12.8%)
Black 7 (8.1%)
Dun 5 (5.8%)
Table 2 Follow-up periods and clinical outcomes post-intravitreal gentamicin injections
Minimum follow-up period Controlled ERU
(no recurrent or
persistent inflammation,
independent of
complications)
Average follow-up
period (days)
Standard deviation
(± days)
Range (days)
30 days 59/86 (68.6%) eyes 52/59 eyes 88.1% 238 190 30–780
3month 43/86 (50.0%) eyes 36/43 eyes 83.7% 313 175 93–780
5month 34/86 (39.5%) eyes 27/34 eyes 79.4% 359 164 153–780
7month 24/86 (27.9%) eyes 20/24 83.3% 407 170 213–780
1 year 12/86 (14.0%) eyes 9/12 eyes 75% 541 137 365–780
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inflammation and prevent recurrent inflammatory bouts
for several years, they are not readily available in Europe
due to legal restrictions governing their importation.
Additionally, there are several instances where PPV (e.g.,
radial retinal detachments, late immature to mature cat-
aracts present) or CSI (e.g., uncontrollable inflammation
despite appropriate medical therapy) are contraindicated.
Thus, additional or alternative treatment options, such
as IVGI, may enable us to better control this highly de-
bilitating disease. attractive.
Aqueous paracentesis and IVGI can be performed dur-
ing the same sedation, using minimal regional and topical
anesthesia; thus, negating the need for general anesthesia.
Ultimately, only those horses not being controlled with
IVGI require additional surgical intervention. This has
dramatically reduced the number of horses requiring sur-
gical intervention to control ERU in our clinic population.
However, if an eye fails to be controlled with IVGI, the
Leptopsira status, previously obtained via aqueous para-
centesis, can then be used to choose the most appropriate
surgical intervention, e.g., a PPV or CSI.
Serum Leptospira antibodies are able to effectively
cross the blood-ocular barriers in the presence of
uveitis, therefore only local antibody production at
the site of the inflamed tissue is a true indicator for a
Leptospira-induced mechanism of action. Individual
aqueous humor or serum antibody titers are unreli-
able predictors of involvement [27]. In order to accur-
ately identify Leptospira’s role in the pathogenesis of
equine uveitis it is important to calculate the c-value
(i.e., the ratio between aqueous humor and serum
antibody titers) [14].
The main goals in treating ERU are the reduction of
ocular inflammation, the reduction or elimination of
pain or discomfort, and the preservation of vision [3,
17]. According to a recent study by Gerding and Gilger,
nearly half of the eyes affected with uveitis became blind,
regardless of the therapy implemented [17]. In a study
from Germany, evaluating the post-operative results fol-
lowing PPV for the treatment of ERU, 17/43 (39.5%) of
the eyes had improved vision, 14/43 (32.6%) of the eyes
demonstrated reduced vision, and 12/43 (27.9%) of the
eyes were blind following the surgery [12]. Long-term re-
sults following implantation of a CSI revealed that 119/
151 (78.8%) of the eyes remained visual [13]. Although the
results of the present study (Table 4) are not directly com-
parable with the previous reports, the vision status of the
eyes in this study remained unchanged following IVGI in
71.2% (42/59) eyes, were improved in 18.6% (11/59) eyes,
and deteriorated in 10.2% (6/59) eyes. Each eye that devel-
oped mature cataracts post-IVGI had some degree of im-
mature cataract maturation prior to IVGI (Fig. 2). Despite
Table 3 Characteristics of uveitis
acute/chronic n = 86 eyes acute
4 (4.7%)
chronic
25 (29.1%)
chronic-acute
57 (66.3%)
recurrent/persistent
n = 86 eyes
recurrent
36 (41.9%)
persistent
50 (58.1%)
presence of aqueous flare
n = 86 eyes
0 (no flare)
42 (48.8%)
1 (faint flare)
20 (23.3%)
2 (moderate flare)
13 (15.1%)
3 (severe flare)
3 (3.5%)
4 (blood or fibrin in
anterior chamber) 8 (9.3%)
Fig. 1 Distribution of clinical signs of uveitis
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this, the degree of cataract maturation prior to IVGI can-
not be reliably utilized to predict the likelihood of cataract
progression/maturation following IVGI. None of the
horses that developed post-IVGI retinal degeneration
demonstrated any subjective behavioral changes (e.g., head
carriage abnormalities (head tilt), spooky or erratic behav-
ior, hesitant to move or navigate obstacles in a known en-
vironment) suggesting that vision was compromised, nor
did they not show detectable clinical signs of vision loss
(menace response). However, we cannot conclude that vi-
sion was not compromised. Additional functional testing
methods, such as pre-IVGI and post-IVGI electroretinog-
raphy (ERG) would provide more objective and meaning-
ful results pertaining to retinal function, and should be
considered for future studies. Although none of the three
eyes that developed retinal degeneration had flare at the
time of IVGI, the clinical disease progression in each of
these horses differed significantly enough to prevent us
from drawing a reliable conclusion as to why this compli-
cation occurred. We cannot exclude that eyes presenting
with a mature cataract did not develop retinal degener-
ation. The risks of potential cataract maturation and retinal
degeneration cannot be ignored, and must be discussed in
detail with the owner when discussing treatment options.
There are many factors that will ultimately determine if an
IVGI is indicated, thus, it is important to provide an accur-
ate risk-benefit analysis for each individual horse. Further
investigation into the post-injection development of retinal
degeneration is warranted. Ongoing efforts include func-
tional testing via ERG and posterior segment evaluation via
optical coherence tomography (OCT). The fact that there
was a significant influence on the development of persistent
inflammation in one eye with multiple positive C-values ≥4
of different Leptospira titers, multiple aqueous humor Lep-
tospira titers ≥1:400 of different serovars and one positive
serum Leptospira titer ≥1:400 warrants further investiga-
tion, but caution must be taken when interpreting this data,
as only a single eye was affected. The complication rates
associated with IVGI (88.1% non-recurrence/non-persis-
tence rate, 8.5% cataract progression/maturation, and
5.1% retinal degeneration) are comparable to published
results following CSI placement (46% non-recurrence rate,
16% cataract progression/formation and 16% retinal
degeneration) and PPV (73.6–100% non-recurrence rate,
38.2–44.2% cataract progression/formation, and 9.3%
retinal degeneration) [9–14].
Presently, the mechanism of action of gentamicin on
the disease process in ERU and other types or stages of
equine uveitis remains enigmatic. Positive suppression of
inflammation, which can be observed as early as 24–48
h post-IVGI, was achieved in various types and stages of
equine uveitis despite the Leptospira status of the eye, in
the present study. Therefore, we speculate that rather
than having a direct bactericidal effect on putative
bacterial organisms, gentamicin instead influences or in-
terferes with the immune-mediated processes intrinsic
to ERU. Although purely speculative, the underlying
mechanism of action of gentamicin may block or sup-
press the activation of specific T-cell lines; cells that are
known to play a significant role in autoimmune uveitis
[28]. Further research into gentamicin’s mechanism of
action following intravitreal injection is necessary.
Limitations of the present study are the short
follow-up periods utilized for evaluation following IVGI.
Despite the short follow-up duration, a 30-day minimum
follow-up period was selected in order to capture the
immediate effects of IVGI and to ensure that all compli-
cations seen associated with this technique were
observed and recorded. Had we selected a longer mini-
mum follow-up period, 1/3 (33.3%) of the eyes that
Table 5 Single c-value results for individual Leptospira serovars
Result C-values for individual Leptospira (L.) serovars
sejroe
(n = 63)
saxkoebing
(n = 63)
canicola
(n = 63)
autum-nalis
(n = 79)
grippo-typhosa
(n = 79)
pomona
(n = 79)
australis
(n = 79)
ictero-haemorrhagiae/
copenhageni (n = 79)
bratislava
(n = 79)
Posititive (+) 0 0 0 1 (1.3%) 15 (19.0%) 4 (5.1%) 1 (1.3%) 1 (1.3%) 1 (1.3%)
Negative (−) 63 (100%) 62 (98.4%) 63 (100%) 74 (93.7%) 54 (68.4%) 69 (87.3%) 75 (95.0%) 77 (95.0%) 75 (95.0%)
Suspicious (?) 0 1 (1.6%) 0 4 (5.1%) 10 (12.7%) 6 (7.6%) 3 (3.8%) 1 (1.3%) 4 (5.1%)
Table 4 Subjective visual assessment pre- and post-IVGI and the subsequent change, or lack thereof, in the individual eyes evaluated
Pre-IVGI n = 86 eyes GOOD
42 (48.8%)
REDUCED
20 (23.3%)
POOR
24 (27.9%)
Post-IVGIn = 59 eyes GOOD
38 (64.4%)
REDUCED
8 (13.6%)
POOR
13 (22.0%)
Change in status following IVGI n = 59 eyes UNCHANGED
42 (71.2%)
IMPROVED*
11 (18.6%)
DETERIORATED**
6 (10.2%)
*from a POOR to a REDUCED or GOOD vision status or from a REDUCED to a GOOD vision status)**from a GOOD to REDUCED or POOR or from REDUCED to
POOR vision status due to cataract formation or phthisis bulbi
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Table 6 Combined serum and aqueous humor Leptospira titer results and the corresponding Leptospira c-value results
Titer negative
titer(s)
SINGLE SEROVAR
positive titer (< 1:400)
MULTIPLE SEROVARS
positive titers (1:100–1:400)
SINGLE SEROVAR
positive titer (> 1:400)
MULTIPLE SEROVARS
positive titers (> 1:400)
Serum
(n = 80)
41 (51.3%) 20 (25.0%) 10 (12.5%) 6 (7.5%) 3 (3.8%)
Aqueous humor
(n = 79)
49 (62.0%) 11 (13.9%) 1 (1.3%) 13 (16.5%) 5 (6.3%)
C-value
(different serovars)
NO positive
c-value
SINGLE positive
c-value (less than 4)
MULTIPLE positive
c-values (less than 4)
SINGLE positive
c-value (greater than 4)
MULTIPLE positive
c-values (greater than 4)
C-value
(n = 79)
50 (63.3%) 12 (15.2%) 1 (1.3%) 11 (13.9%) 5 (6.3%)
a b c
d
e
f
g
Fig. 2 Nine-year old warmblood gelding presented with chronic-acute, persistent panuveitis of the right eye (OD). Negative c-value for Leptospira. a. Initial
presentation: Blepharospasm, epiphora, diffuse corneal edema, 360° corneal neovascularization, + 4/4 flare, fibrin in anterior chamber and miosis were
present. The posterior aspect of the eye could not be visualized. Inflammation was controlled with medical therapy. b. One-hundred-fifteen
days post-initial presentation: Two additional bouts of inflammation since initial presentation. Both intravitreal gentamicin injection (IVGI) and
aqueocentesis were performed. Immature cataract and posterior synechia were present at the time of IVGI OD. c. Seven days post-IVGI OD: Immature
cataract. d. Sixty days post-IVGI OD: Medical treatment was discontinued 39 days prior to this examination. No signs of active inflammation could be
identified. e. One-hundred-thirteen days post IVGI OD: Mature cataract (cataract maturation). No signs of active inflammation. f. Three-hundred-twenty-seven
days post-IVGI OD: Uveitis remains controlled without medical treatment. g. Six-hundred-two days post-IVGI OD: No recurrent bouts of inflammation
since IVGI
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developed retinal degeneration and 1/5 (20%) of those,
where cataract progression was observed would have
not been included in our results, thus introducing a
false positive bias into our complication rates. One
cataract, that would not have been included other-
wise, developed when using preservative-free gentami-
cin. Thus, setting the minimum-follow-up period at a
time point further out from the IVGI (e.g., 5 months)
would have prevented inclusion of those complica-
tions from our results, as a result, an incorrect
conclusion would have been drawn that no cataract
progression/maturation occurred when utilizing PFG
for the IVGI. Future studies evaluating the clinical
outcome and the presence or development of
long-term complications over multiple years are ne-
cessary and are currently underway.
The present study reports control of ERU in 88.1%
(non-recurrence/non-persistence rate) in the absence of
medical treatment of the eyes with a minimum
follow-up period of 30 days. These results support the
a b1 b2
c d e
f
g
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Fig. 3 Eight-year old warmblood mare that presented for chronic-acute, recurrent anterior uveitis in the left eye (OS). Negative c-value for
Leptospira. a. Initial presentation: Two days following the onset of an acute bout of inflammation. Topical and systemic therapy were initiated by
the referring veterinarian, when ocular signs were first identified. Inflammation was controlled via medical therapy. b1. Seven months after initial
presentation: Active uveitis OS; + 4/4 flare, fibrin and complete miosis were present. b2. Infrared picture of OS at the same examination as in B1.
c. Uveitis was controlled within 5 days of initiating medical therapy. d. Recurrent acute inflammation: 14 months later. Intravitreal gentamicin
injection (IVGI) and aqueocentesis were performed. e. Ninety-eight days post-IVGI OS: Uveitis has remained controlled following IVGI. A focal area
of tapetal hyperreflectivity identified during indirect ophthalmoscopy of the fundus. f. Fundus image of the lesion described in e. Retinal
degeneration developed between the 30- and 98- day recheck examination. Subjective vision status unchanged from pre-IVGI. g. Two-hundred-seventy
days post-IVGI OS: Uveitis controlled. Retinal degeneration remains static. h. Three-hundred-eighty-five days post-IVGI OS: Uveitis remains controlled. Retinal
degeneration remains static
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anecdotal findings reported by Pinard in 2005 with a
positive outcome of 94.4%, and those reported by
Kleinpeter in 2014 showing a positive outcome in 93.3%
(follow-up: 2–96month) [25, 29]. In the latter study, 11/
60 (18.3%) eyes became blind due to cataract formation
following IVGI [25]. When comparing this result to the
first 34 eyes in the present study that were treated with
gentamicin containing preservatives, similar rates of
cataract formation or maturation (4/34 (11.8%) eyes)
were observed [25]. Because cataract maturation was ob-
served most often in eyes with moderate pre-existing
cataracts, we speculated that the preservatives in Genta
100 may have contributed to the accelerated cataract
maturation in these cases. In order to minimize this risk,
we switched to PFG solution after making this ob-
servation. After switching to PFG, only a single cata-
ract progressed from immature to mature (1/52 eyes,
1.9%). Although the exact risk of cataract maturation
associated with PFG IVGI is unknown, it appears
that utilization of a PFG solution may help to
minimize the actual risk of developing this blinding
complication post-IVGI.
Conclusion
With less than 9% of the horses in the present study
developing recurrent or persistent inflammation, less
than 9% with cataract maturation and less than 6%
with retinal degeneration, IVGI was associated with a
lower level of complications compared with medical
therapy [3, 17, 18] and other commonly implemented
surgical treatment options for ERU (CSI placement
and PPV) [10–13]. The ability of low-dose IVGI with
4 mg gentamicin (especially PFG) to suppress active
inflammation in various types and stages of equine
uveitis in the present study despite the Leptospira sta-
tus of the eye, adds another treatment option in the
management of a severely debilitating and vision
threatening disease.
Methods
Case selection
Complete initial and all follow-up ophthalmic examina-
tions were performed by a board-certified veterinary
ophthalmologist (RJM) between January 2013 through
June 2016 in south-east Germany. Horses presenting
with signs of active or chronic uveitis and a history of
recurrences were included in the study. Signs associated
with recurrent or persistent uveitis included, but were
not limited to, blepharospasm, epiphora, keratic pre-
cipitates (KP), aqueous flare, fibrin in the anterior
chamber (AC), hyphema, miosis, corpora nigra atro-
phy or degeneration, iris hyper- or depigmentation,
equatorial vesicular cataracts, posterior lens capsule
adhesions or opacifications, vitreous body opacifica-
tions, and retinal detachment. Horses with uveitis
resulting from putative trauma, secondary to infec-
tious corneal diseases, or following intraocular sur-
gery, were excluded.
Owners were educated on the various medical and
surgical (i.e., PPV, CSI, and intravitreal injections) treat-
ment options, and risks associated with each option.
Client consent to perform the IVGI was obtained follow-
ing an in-depth discussion of potential complications
including failure of the selected treatment option to
control the disease, resulting in persistent/ recurrent in-
flammation with progression of ocular signs, and poten-
tial cataract maturation or development and retinal
degeneration or detachment.
Examination
Complete ophthalmic examinations were performed on
initial presentation, and on each subsequent follow-up
examination, and consisted of a subjective clinical vision
assessment (menace response) and neuro-ophthalmic
evaluation (dazzle, and pupillary light reflexes (PLR)),
slit lamp bio microscopy (Kowa SL-15),1 indirect oph-
thalmoscopy (Keeler Vantage),2 rebound tonometry
(TonoVet),3 external ocular fluorescein dye
Table 7 Individual variables with positive correlation to treatment outcome or the development of post-injection complications
Variable Treatment Outcome Post-Injection Complications
Breed Appaloosas: more recurrent inflammation than other breeds NC
Coat color Leopard patterned: more recurrent inflammation than other
coat colours
NC
Flare pre-IVGI NC NO flare: increased risk of retinal degeneration
Leptospira status of the eye Multiple positive C-values (≥4) for multiple individual
serovars: increased incidence of persistent inflammation
NC
Aqeuous humor titer in total Multiple positive individual aqueous humor titers for Leptospira
(≥1:400): increased incidence of persistent inflammation
NC
Single serum titer One positive serum titer for Leptospira (≥1:400): increased
incidence of persistent inflammation
NC
Abbreviations: NC no correlation
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Each case was further categorized as “acute” (active
inflammation without overt signs of chronicity),
“chronic” (signs of chronicity but no signs of active in-
flammation) or “acute/chronic” (acute onset of inflam-
mation associated with chronic inflammation).
“Recurrent uveitis” was diagnosed when at least 2 epi-
sodes of recurrent inflammation occurred despite appro-
priate medical therapy leading to a period of quiescence
following cessation of medical therapy. “Persistent in-
flammation” was diagnosed when an initial or recur-
rent bout of inflammation remained actively inflamed
for a minimum of four weeks despite aggressive and
appropriate medical or surgical therapy (Fig. 4).
The subjective vision status prior to, and following,
IVGI was graded as “good” (positive menace, dazzle,
direct and indirect PLR, with no evidence of obvious
visual field impairment due to corneal edema,
hyphema, hypopyon, fibrin in the anterior chamber,
miosis, synechia, lens opacities/cataracts, vitreal de-
generation, fundus abnormalities), “reduced” (positive
menace, dazzle, direct and indirect PLR with some
evidence of visual field impairment due to the abnor-
malities listed above) and “poor” (negative or positive
menace, dazzle and direct and indirect PLR with ob-
vious evidence of visual field impairment (late imma-
ture to mature cataracts), retinal degeneration/
detachment, or phthisis bulbi).
a b c
d e
Fig. 4 Twelve-year old warmblood mare that presented for a chronic-acute persistent panuveitis of the left eye (OS). Negative c-value for
Leptospira. a. Initial presentation: Diffuse corneal edema, keratic precipitates, + 2/4 flare, fibrin, vitreal degeneration and retinal folds were present.
Medical treatment was started (prednisolone acetate q 4–6 h, atropine q 8 h and flunixine meglumine 1.1 mg/kg twice daily). b. Ten days post
initial presentation: The clinical signs worsened in the face of aggressive medical treatment. Intravitreal gentamicin injection and aqueocentesis were
performed OS. c. Four days post-IVGI OS: Improvement of clinical signs can be readily appreciated. d. Twenty days post-IVGI OS: No flare present. e.
Forty-nine days post-IVGI OS: Uveitis remains controlled without medications. The mare was euthanized due to complications associated with cervical
spinal fracture 2months after IVGI
application (Fluoreszein SE Thilo),4 and color (Nikon 
D300s)5 and infrared (Nikon D200)5 (sensor conver-
sion)6 digital imaging. Aqueous flare was graded as 
follows: 0 (none), 1 (faint), 2 (moderate), 3 (severe) or 
4 (blood or fibrin present in the anterior chamber)
[30]. Fundus images (Kowa Genesis or ClearView)1,7 
were obtained in horses with posterior segment abnor-
malities, when possible.
Categorization of uveitis
For statistical purposes, each case was diagnosed with 
one of the following: 1. Panuveitis (global uveal inflam-
mation with equal distribution of clinical signs between 
the anterior and posterior segment); (Figs. 2 and 4); 2. 
Panuveitis with predominant anterior segment involve-
ment; 3. Panuveitis with predominant posterior segment 
involvement; 4. Anterior uveitis; (Fig. 3); 5. Posterior 
uveitis; and 6. Heterochromic iridocyclitis with second-
ary keratitis (HIK), a recently described, specific form of 
idiopathic anterior uveitis (iridocyclitis) and corneal 
endothelial inflammation associated with iris pigment 
dispersion and retro-corneal fibrous membrane forma-
tion [2, 3, 8, 31].
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real-time PCR was used for the detection of Leptos-
pira DNA in the aqueous humor [35]. With the help
of the C-value (dividing the aqueous humor Leptos-
pira antibody titer by the serum Leptospira antibody
titer), eyes were categorized into Leptospira “positive”
(C-value greater than 3), “Leptospira suspicious”
(C-value between 1 and 3) and “Leptospira negative”
(C-value of 0) for statistical evaluation [27, 36].
Post-injection therapy
Post IVGI medical therapy consisted of topical antibi-
otics (Ofloxacin)22 q8h for one week, and topical corti-
costeroids (Prednisolone acetate)23 or nonsteroidal
anti-inflammatory drugs (NSAIDs) (Bromfenac)22 that
were gradually tapered over the course of 4–8 weeks based
on each horse’s individual response to therapy. Either 1%
tropicamide24 or 1% atropine25 were applied topically for
a variable duration to maintain or achieve mydriasis and
to stabilize the blood aqueous barrier. Systemic NSAIDs
(flunixin-meglumine, 0.55mg/kg, p.o., q12h)9 were also
administered per os and gradually tapered-off over the
course of 7 to 14 days. A prophylactic dose of 37% omep-
razole (Gastrogard, 2mg/kg p.o.)26 was routinely adminis-
tered orally, once daily while using systemic NSAIDs.
Follow-up examination
Following IVGI all eyes were immediately examined for the
presence of peri-injection complications (subconjunctival
or intracameral hemorrhage), and re-examined within 24 h.
Horses were monitored weekly for the first month or until
medications were discontinued. Subsequent follow-up ex-
aminations were spaced further apart based on the horse’s
individual response to treatment. Inflammation was consid-
ered controlled if no signs of recurrent or persistent uveitis,
independent of complications, were identified at any
follow-up examination after medications had been discon-
tinued. Particular attention was paid at all times to the pos-
sible development of post-injection complications (cataract
formation/maturation, retinal degeneration).
Data analysis
All 86 eyes were evaluated for peri-injection complica-
tions (subconjunctival and intracameral hemorrhage),
but only those with a minimum follow-up period of 30
days (59 eyes) were included in the post-injection statis-
tical data evaluation. These latter eyes were monitored
for signs of recurrent or persistent inflammation, as well
as for the presence of additional complications or seque-
lae (e.g., cataract formation/progression and retinal
degeneration). Correlation between the outcome
(controlled, recurrent, or persistent inflammation),
post-injection complications (no complications, cata-
ract formation or maturation, and retinal degener-
ation), and possible influencing factors (breed, coat
Sedation, intravitreal gentamicin injection and aqueous 
paracentesis
A general physical examination including auscultation 
and body temperature measurement was performed 
prior to sedation with a combination of detomidine 
hydrochloride (Domosedan, 0.01–0.02 mg/kg bwt i.v.)8 
and butorphanol (Alvegesic, 0.005–0.01 mg/kg bwt i.v.)9 
intravenous and intramuscular bolus (0.02–0.04 mg/kg 
bwt i.m.) injections. Blood (serum and EDTA) was 
drawn and submitted for a complete blood count and 
chemistry panel. A microscopic agglutination test 
(MAT) for Leptospira antibodies was also routinely per-
formed [32]. A total of nine serovars (L. bratislava,10 L. 
icterohaemorrhagiae/copenhageni10, L. australis10, L. po-
mona10, L. grippotyphosa10, L. autumnalis10, L.cani-
cola,11 L. saxkoebing11, L.sejroe11) were evaluated10,11 .
Following sedation, the horse’s head was positioned 
atop a pair of pads placed on a mobile cart to increase 
stability. Local akinesia and analgesia (palpebral and the 
frontal nerve blocks) was achieved using 2% mepivacaine 
(Scandicain 2%)12 [33]. Topical anesthetic ophthalmic 
solution (proparacaine HCL 0.5%)13 was applied as 
needed. The conjunctival fornices were irrigated with 
1.0 ml of a dilute baby shampoo solution14 (1 ml of baby 
shampoo in 1 l of balanced saline solution), 1.0 ml of a 
1.0% dilute iodine solution,15 and 1.0 ml of balanced 
saline solution (Acrisol)4 [34].
Dorsal globe exposure was facilitated with either a 
Desmarres16 or prototype eyelid retractor,17 and further 
enhanced by rotating the horse’s head away from the exam-
iner to exaggerate ventral globe rotation. The first 34 horses 
were treated with a 4 mg injectable gentamicin solution 
containing preservatives (Genta100; 100 mg/ml)9. All add-
itional horses (n = 52) were treated with preservative-free 
gentamicin (PFG) (Gentamicin-ratiopharm, 160 mg/2 ml 
SF).18 Undiluted gentamicin (0.04 ml Genta100 or 0.05 ml 
PFG) 9,18 was drawn up in a 30- gauge needle/syringe 
combination (12 mm length, 1.0 ml insulin syringe), and 
the IVGI was performed using headloupes (magnification)
(Eschenbach MaxView with LED light source or 
headloupes with a separate head-mounted light source 
(ML4-LED))19,20,.21 The injection site was 10 mm posterior 
to the limbus at 12 o’clock. Injection was facilitated by 
applying gentle but steady pressure while slowly and delib-
erately rotating the needle in a clockwise manner with the 
needle directed toward the optic nerve head to avoid inad-
vertent contact with the lens. Aqueous paracentesis was 
then performed using a second insulin syringe at either the 
11:00 o’clock (right eye, oculus dexter, OD) or 1:00 o’clock 
(left eye, oculus sinister, OS) positions. A total volume of 1 
ml aqueous humor was aspirated. Aqueous humor and 
serum samples were refrigerated prior to transport to the 
laboratory. MAT tests for Leptospira titers were per-
formed with the serum and aqueous humor, and
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3.2 Medical and Surgical Management of Equine Recurrent Uveitis 
Own contribution:  
The following tasks which are part of the second publication, have been performed by 
myself 
• Literature research
• Evaluation of own clinical experience
• Manuscript preparation
The tasks of the other author of this publication were the study design, manuscript 
preparation, revision and editing (Dr. R. McMullen). 
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Medical and Surgical
Management of Equine
Recurrent Uveitis
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INTRODUCTION
Equine recurrent uveitis (ERU) is a widely recognized, complicated, multifaceted dis-
ease that is characterized by multiple, recurrent bouts of inflammation interrupted by
variable periods of quiescence.1–6 True recurrences of inflammation occur following
complete elimination of inflammatory signs (eg, keratic precipitates [KPs], aqueous
flare, miosis, cortical [equatorial] cataracts, vitreal opacification, fundus or optic nerve
head [ONH] lesions) via topical and systemic antiinflammatory and immunosuppres-
sive medication.1,5,6 When medical therapy is withdrawn too soon, it may appear as
if the inflammation returns within a short period of time (often 2–6 weeks). However,
in many cases the signs associated with ERU had not been completely eliminated,
but merely suppressed, giving the appearance that the eye had reached a stage of
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KEY POINTS
 Primary uveitis (isolated bouts of inflammation) must be differentiated from recurrent uve-
itis (multiple bouts of inflammation interrupted by periods of quiescence).
 Medical therapy/management alone leads to severe loss of vision or blindness in greater
than 50% of all affected horses.
 There is a breed predilection for ERU in Appaloosa, draft, Knabstrupper, Icelandic, and
warmblood breeds.
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quiescence. This premature cessation of medications often occurs if the eyes become
comfortable and subtle signs of inflammation (eg, KPs, aqueous flare, vitritis, inflam-
mation of the ONH [optic neuritis]) are missed during reexamination (Fig. 1). This sit-
uation is referred to as a pseudorecurrence and can lead to a misdiagnosis or, worse,
to progressive intraocular changes resulting in decreased vision or blindness if it goes
undetected.2
A recent study from western Canada reported that 12 out of 32 (38%) horses with
ERUwere bilaterally blind on presentation and 20 out of 26 (76.9%) were bilaterally blind
at the last follow-up, and 17 out of 20 (85%) of these blind horses were euthanized.7 In
another study from the southeastern United States, 96 out of 338 (28%) of the eyes pre-
senting with ERU were blind on initial presentation.8 Forty-one out of 338 (12.1%) eyes
were enucleated and 29 out of 224 (14.9%) of the horses were euthanized.8 Both of
these studies reveal that too many horses are being referred far too late in the disease
process (Fig. 2).7,8 Therefore, it is essential that horses showing subtle clinical signs that
are not immediately associated with ERU (intermittent redness [conjunctival hyperemia],
tearing [epiphora], squinting [blepharospasm]) should be thoroughly examined for addi-
tional signs associated with chronic or recurrent uveitis (KPs, aqueous flare, miosis,
decreased intraocular pressure [IOP]). This approach will allow for targeted therapy to
be administered early in the disease process, which may prevent more severe second-
ary complications from developing, and will initiate a reevaluation pattern by owners,
referring or primary veterinarians, and veterinary ophthalmologists alike, which may in-
crease the likelihood of preserving vision.
There are several alternative treatment approaches that may prove useful in the
earlier stages of intervention and may result in fewer horses losing vision or
requiring more invasive surgical intervention to control inflammation caused by
ERU. Such treatment options include intravitreal gentamicin (IVG) injections,9–11
intravitreal triamcinolone injections,12 intravitreal rapamycin injections,13 supra-
choroidal space injections of triamcinolone,14 surgical placement of suprachoroidal
cyclosporine sustained-release devices (cyclosporine implants),15,16 and pars
plana vitrectomy.17–19 Diagnosing ERU and selecting the most appropriate treat-
ment option is tedious, difficult, and riddled with setbacks. Conservative medical
therapy provides the foundation of therapy and should be initiated in every case
Fig. 1. Although the eye is open and comfortable, a moderate number of endothelial KPs
remain visible during direct retroillumination. The dark, pinpoint KPs appear refractile dur-
ing retroillumination. The pupil has been pharmacologically dilated.
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of uveitis. Once all signs of inflammation have resolved, medical therapy can be
discontinued. It is important that the antiinflammatory and immune-suppressive
drugs are tapered off over a prolonged course of treatment (generally, 6–8 weeks)
for 2 reasons. First, if the inflammation is not well controlled, clinical signs may
worsen during the slow tapering of drugs, allowing for prompt increases in medica-
tion frequencies to again quickly suppress the inflammation. Second, stopping
topical and systemic antiinflammatory and immunosuppressive therapy after 14
to 21 days, when subtle signs of inflammation (aqueous flare, pinpoint KPs) may
be overlooked without careful examination, leads to the development of pseudor-
ecurrences.2 The return of bouts of inflammation in these situations is not caused
by a new round of active uveitis but by a slow resurfacing of clinical signs of uveitis
associated with the previous bout of insufficiently suppressed inflammation (Fig. 3).
Fig. 2. Chronic and insidious panuveitis with corneal fibrosis and neovascularization, a
shallow anterior chamber, rubeosis iridis (vascular engorgement of the iris vessels), and a
ventrally displaced pupil (corectopia). The anteriorly displaced lens is entrapped posterior
to the dorsal iris (note the spherical anterior protrusion in the dorsal portion of the iris).
Fig. 3. (A) Right eye (oculus dexter [OD]) of a 20-year-old thoroughbred mare with chronic
ERU 2 weeks following bilateral low-dose intravitreal injections of preservative-free genta-
micin (4 mg) and topical and systemic antiinflammatory and immunosuppressive treatment.
The pupil is only midrange, despite topical treatment with atropine. Note the degeneration
of the corpora nigra and focal pigment deposition along the anterior lens capsule. Periph-
eral corneal neovascularization remains present, but is difficult to see because of the darkly
pigmented iris. (B) Left eye (oculus sinister [OS]) of the horse from (A). The pupil is irregu-
larly shaped (dyscoria), the corpora nigra show moderate degeneration, and there are focal
adhesions between the pupil and anterior lens capsule (posterior synechiae) at both the 2:30
and 8:00 o’clock positions. Peripheral corneal neovascularization is present, but difficult to
visualize, in this eye too. (C) A view of the same mare from the front reveals a yellow tapetal
reflex, indicating that there is still significant inflammation present in both the anterior
chamber and vitreous of both eyes (oculus uterque [OU]).
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That is, these eyes never reach a true state of quiescence (periods without inflam-
mation between separate bouts of active inflammation). Unrecognized pseudore-
currences may be mistaken for recurrent bouts of inflammation, suggesting that
the underlying inflammation is more severe than may be the case. However, the
development of pseudorecurrences can prove to be just as serious, if not more
so, as a recurrent bout of inflammation recurring after a longer period of quiescence
because the increased signs associated with the recurrences cause repeated and
amplified damage to an already vulnerable eye.2 Ensuring that a true state of quies-
cence is reached by gradually tapering medications over a prolonged period of time
helps to accurately assess the horse’s underlying state of inflammation. Recur-
rences that occur frequently (every 3–4 months, or less), and require longer dura-
tions of treatment before the signs of inflammation subside, are more likely to
develop debilitating ocular complications associated with ERU (marked aqueous
flare, fibrin accumulation in the anterior chamber [Fig. 4], posterior synechia
[Fig. 5], vitritis, retinal folds or degeneration [Fig. 6], optic neuritis [Fig. 7]) or go
blind than eyes with annual recurrent bouts of inflammation associated with mini-
mal signs of disease (trace to mild flare, fine KPs [see Fig. 1], and miosis
[Fig. 8]). Presently, there are several treatment options to reduce or prevent recur-
rent inflammation and that help to maintain vision in horses with ERU.9–19
PATIENT EVALUATION OVERVIEW
A detailed history is essential and can help to identify initial and mild recurrences,
which often go unnoticed. Episodes of conjunctival hyperemia (redness), tearing (epi-
phora), and/or squinting (blepharospasm) that wax and wane are often reported by
owners as being present before any so-called real eye problems develop. Many hors-
es with ERU have 1 or several of the episodes described earlier during the years before
clinical presentation. A heightened awareness or sensibility for the findings described
earlier may lead to earlier recognition, earlier diagnosis, and ultimately to the earlier
implementation of targeted treatment (Table 1).
Fig. 4. (A) The left eye (OS) of a quarter horse yearling with a large fibrin clot in the ante-
rior chamber. Note the other signs of severe uveitis: marked rubeosis irides, iris depigmen-
tation and corpora nigra degeneration, and murky yellow tapetal reflex consistent with
moderate aqueous flare and vitreal opacification. (B) Using tangential illumination (light
directed obliquely from the temporal limbus) the superficial iris vessels (rubeosis irides)
and the fibrin clot can be visualized with much more detail. Note the fibrin adhered to
the corpora nigra along the dorsal edge of the pupil. (C) This handheld slit lamp image
shows the thickened ventral cornea and partial adhesion of the fibrin to the corneal endo-
thelium. Also note the smooth surface of the corpora nigra, which is visible just above the
dorsal aspect of the fibrin clot occupying the entire depth of the anterior chamber
(yellowish material between the white corneal light reflex and light brown slit of light
along the surface of the iris).
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 ERU may also be further differentiated according to stages of chronicity, with
cases being labeled as active (Fig. 9), quiescent (Fig. 10), or end stage (Fig. 11).
 The following anatomic diagnoses may make differentiation easier: panuveitis;
panuveitis with predominant posterior signs; panuveitis with predominant ante-
rior signs; anterior uveitis; posterior uveitis (Fig. 12); and heterochromic iridocy-
clitis with secondary keratitis (Fig. 13 and Table 2).20
Fig. 5. Chronic recurrent panuveitis with predominantly anterior signs. Note the small tuft
of fibrin near the iridocorneal angle of the anterior chamber at 8:30 o’clock. There is also
marked posterior synechiae and diffuse pigment deposition along the anterior lens capsule.
Note the thin, white, membranous veil containing pigment (fine punctate spots) spanning
the ventral width of the pupil.
Fig. 6. The tapetal fundus of this 8-year-old quarter horse mare is markedly and diffusely
hyperreflective, and there are multiple retinal folds manifest as linear bands extending radi-
ally from the ONH. This clinical presentation is very severe. Note the small area of subretinal
cellular infiltrate along the 12:00 o’clock edge of the ONH.
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 With chronicity, regardless of which type of ERU is present, corneal vasculariza-
tion, endothelial degeneration resulting in persistent corneal edema, linear
corneal calcification (especially within and parallel to the palpebral margins), pos-
terior (occasionally anterior) synechiae, cataract formation, and alterations in iris
color and surface appearance commonly occur. Secondary glaucoma and
phthisis bulbi can occur, ultimately resulting in irreversible blindness in many
cases of ERU.
Fig. 7. The ONH in this horse with chronic recurrent panuveitis is moderately edematous
and hyperemic. During binocular indirect ophthalmoscopy the anterior displacement of
the thickened (edematous) peripapillary retina can be readily appreciated.
Fig. 8. (A) Miosis in the left eye (OS) of a 6-year-old quarter horse gelding. This active
bout of inflammation recurred following early cessation of topical and systemic medica-
tions. This pseudorecurrence presented with marked blepharospasm, corneal neovascula-
rization, and a shallow anterior chamber, with hypopyon (ventral iridocorneal angle),
miosis, fibrin accumulation in the anterior chamber, and diffuse iris hypopigmentation.
The corpora nigra are also atrophied (this is easier to visualize in the infrared image
[B]). (B) Infrared image of OD from (A). Note that the pupil, degenerative/atrophied
corpora nigra, and the fibrin veil in the anterior chamber are easier to visualize in the
infrared image.
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Table 1
Classification of equine recurrent uveitis
Categories
of ERU Description Tissue Affected
Anatomic
Diagnosis
Breed
Predisposition
Classic  Active bouts of
inflammation
 Followed by vari-
able periods of
quiescence
Primary:
Uvea (iris, ciliary
body, choroid)
Secondary:
Cornea, anterior
chamber, lens,
vitreous, retina
 Panuveitis
 Panuveitis
(anterior)
 Panuveitis
(posterior)
 Anterior uveitis
 HIK
Warmblood
Icelandic
horses
Insidious  Low-grade intra-
ocular
inflammation
 Not outwardly
painful
 Gradual tissue
destruction
 Degeneration of
multiple intraoc-
ular structures
 Posterior segment
inflammation
initially
 Anterior segment
inflammation
follows
 End-stage eyes
globally affected
 Panuveitis
 Panuveitis
(anterior)
 Panuveitis
(posterior)
 HIK
Appaloosa
Draft breeds
Knabstrupper
Posterior  Acute bouts of
inflammation are
severe and
respond slowly to
medical therapy
 Predominantly
posterior segment
inflammation
 Mild anterior
inflammation is
common
 Posterior
uveitis
 Panuveitis
(posterior)
 Panuveitis
Warmblood
Abbreviation: HIK, heterochromic iridocyclitis with secondary keratitis.
Fig. 9. (A) Active inflammation in the right eye (OD) of an 8-year-old bay warmblood mare
with chronic recurrent panuveitis with predominantly anterior segment involvement. There
is circumferential superficial corneal neovascularization and diffuse corneal haze, as well as
a very shallow anterior chamber with complete miosis and fibrin and hyphema within the
pupil. The iris is diffusely hyperpigmented and the posterior segment could not be visual-
ized clinically. On ocular ultrasonography, only minimal vitreal hyperechogenicity could
be appreciated. (B) Digital infrared image of the eye from (A). Despite the iris hyperpigmen-
tation, a much better appreciation for the iridocorneal angle and pupil margin can be ob-
tained with this method of clinical imaging.
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 It is important to consider/remember that current classifications of equine uveitis
and ERU do not specifically differentiate between anatomic location (eg, anterior
uveitis, posterior uveitis, and panuveitis) or clinical manifestation, but combine
several potentially different clinical presentations into broader disease syn-
dromes that are essentially a combination of several different individual
classifications.
Fig. 10. Quiescent stage in the right eye (OD) from an 11-year-old bay warmblood gelding
with a 3-year history of chronic recurrent inflammation that was only controlled while on
high levels of immunosuppressive medications. He was ultimately treated with an intravi-
treal injection of low-dose gentamicin (4 mg). Although his eye had significant chronic signs
of inflammation and secondary complications from ERU (he had significant discomfort,
marked corneal vascularization, diffuse corneal fibrosis, complete miosis, and a mature cata-
ract at the time of injection), he has remained free from recurrent bouts of inflammation for
more than 602 days postinjection.
Fig. 11. End-stage uveitis. Phthisis bulbi (shrunken globe) with marked corneal vasculari-
zation, linear corneal fibrosis (representing folds in the cornea as a consequence of
extremely low intraocular pressure), complete loss of anterior chamber depth, secluded
pupil, and marked depigmentation of the iris. The posterior segment was not visible clin-
ically, but ocular ultrasonography revealed moderate vitreal opacification and retinal
detachment.
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PHARMACOLOGIC TREATMENT OPTIONS
Conventional Medical Therapy
Details of conventional medical therapy are given in Tables 3–5.
Long-term Control and/or Prevention of Recurrent Bouts of Inflammation
Conventional antiinflammatory and immunosuppressive medical therapy is necessary
to reduce/eliminate inflammation and indirectly minimizes secondary ocular damage
occurring as a result of each recurrent bout of inflammation. However, even when
effective, conventional medical therapy cannot prevent recurrent bouts of inflamma-
tion. There are several other treatment options available that may effectively postpone
or prevent such recurrences.
Fig. 12. Chronic, recurrent posterior uveitis in a 9-year-old Icelandic horse gelding. There is
significant vitreal inflammation (vitritis) present, which can be readily identified through
the pharmacologically dilated pupil. There are small, focal, anterior cortical cataracts asso-
ciated with focal pigment deposition from recurrent bouts of inflammation but a relative
lack of anterior segment signs.
Fig. 13. (A) Left eye (OS) and (B) right eye (OD). Heterochromic iridocyclitis with secondary
keratitis (HIK; endotheliitis) in a 12-year-old, bay warmblood gelding. Note the fine punc-
tate (OS) and larger focal (OD) corneal opacifications and ventromedial areas of focal
corneal edema. These findings, along with the diffuse depigmentation and iris atrophy/
degeneration, are characteristic of this type of anterior uveitis.
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NONPHARMACOLOGIC TREATMENT OPTIONS
Leptospira Vaccination
Leptospirosis, the intraocular (vitreous) sequestration of leptospiral antibodies, or the
organism itself has been associated with ERU for decades.21–28 Despite this fact,
there is little known on the pathophysiology of leptospiral-induced ERU. Because
leptospiral detection (antigen or antibodies) is not routinely performed, the prevalence
of leptospiral-induced ERU remains enigmatic. A study from Zurich, Switzerland,
described a useful protocol for ERU patient selection to better determine which horses
are the best candidates for vitrectomy surgery.29 A recent study from Germany, eval-
uating the use of low-dose IVG (4 mg) in which each horse was evaluated for the pres-
ence of leptospiral and equine herpesvirus (EHV) DNA (aqueous humor) and
leptospiral antibody titers (serum and aqueous humor), showed that the overall expo-
sure to leptospiral organisms is high (63 out of 79 eyes; 79.75%; C-value, 0–3), but that
the presence of a C-value greater than 3 (indicating intraocular antibody production)
Table 2
Clinical signs associated with equine recurrent uveitis
Categories
of ERU
Clinical Signs
SequelaeAcute Chronic
Classic  Increased lacrimation
 Blepharospasm
 Miosis
 Photophobia
 Aqueous flare
 Intraocular fibrin
 Hyphema
 Hypopyon
 Miosis
 Low IOP
 Cataract formation/
progression
 Phthisis bulbi
 Posterior synechiae
 Misshapen pupil
 Intermittent increases
in IOP with chronicity
 Severe vision loss and/
or blindness
Insidious  Not outwardly painful
 Generally not de-
tected until later
stages of disease
 Conjunctival and epis-
cleral vascular
hyperemia
 Mild to moderate
blepharitis
 Aqueous flare
 Focal or diffuse corneal
edema (dull or lack-
luster appearance)
 Iris atrophy/corpora ni-
gra degeneration
 Iris discoloration
 Hyperpigmentation
 Hypopigmentation
 Lens subluxation or
luxation
 Anterior or posterior
 Shallow anterior
chamber
 Absent or sluggish
pupillary light reflexes
 Posterior synechiae
 Pigment on anterior
lens capsule
 Pupillary occlusion
 Focal/diffuse cataracts
obscure visualization of
the posterior segment
 IOP generally low
 <12 mm Hg
 Secondary glaucoma is
common
 Grave prognosis for
maintaining vision
Posterior  Vitritis
 Chorioretinal scarring
 Retinal degeneration
 Optic neuritis
 Subtle anterior
segment signs:
 KPs
 Aqueous flare
 Miosis
 Blepharospasm
 Active/inactive
chorioretinitis
 Focal or diffuse retinal
detachments
 Peripapillary retinal
folds
 Vitreous: cloudy/hazy
appearance
 ONH and surrounding
retina may appear
congested
 Bullet-hole lesions
 Butterfly lesions
 Prevalence associated
with ERU unknown:
lesions not
commonly seen with
ERU
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was seen in only 16 out of 79 eyes (20.25%) of the horses tested.11 The roe of EHV in
ERU remains to be determined, but preliminary evaluation of the data mentioned
earlier indicate that EHV-2 or EHV-5 DNA can be simultaneously detected in severe
cases of ERU.11 This information may become useful in the future when trying to deter-
mine the significance of leptospiral titers, especially in the context of vaccination. In
addition, leptospiral vaccination in dogs can result in seroconversion, leading to
increased titers from serovars other than Pomona.30 If this occurs in horses, it will
Table 3
Topical medications for equine recurrent uveitis
Drug Class Medications Frequency Pros Cons
Corticosteroid Prednisolone
acetate 1%
q 4–6 h Potent
Excellent ocular
penetration
Immunosuppressive,
predisposes to
secondary corneal
fungal infections
Dexamethasone
0.1%
q 4–6 h Potent
Excellent ocular
penetration
Immunosuppressive,
predisposes to
secondary corneal
fungal infections
NSAIDs Flurbiprofen,
diclofenac,
suprofen, or
bromfenac
q 8–24 h Good additional
antiinflammatory
medication alone or
in conjunction with
corticosteroids
May be used when a
corneal ulcer is
present
May not be as
effective as
corticosteroids in
acute phase of
disease
Mydriatic Atropine HCl 1% q 4–24 h Decreases iris muscle
spasm (cycloplegia),
induces mydriasis,
minimizes synechia
formation,
stabilizes blood-
ocular barriers
May decrease gut
motility
Monitor for signs of
colic
Pupil remains dilated
for up to 21 d in
normal eyes
Abbreviation: q, every.
Table 4
Subconjunctival medications for equine recurrent uveitis
Drug Class Medications Frequency Pros Cons
Corticosteroids Methylprednisolone
acetate (40 mg)
q 1–3 wk Duration
of action,
7–10 d
Markedly increased risk
of secondary
infections (fungal or
bacterial)
Cannot be removed
once administered
Triamcinolone
acetonide (1–4 mg)
q 1–3 wk Duration
of action,
7–10 d
Markedly increased risk
of secondary
infections (fungal or
bacterial)
Cannot be removed
once administered
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confuse things further. Therefore, it will become even more important in the future to
evaluate both serum and aqueous humor for leptospiral titers and DNA and to
correlate these results with the disease history and clinical signs present on
presentation.11,29
COMBINATION THERAPIES
Intravitreal injections are routinely used in human ophthalmology to manage various
forms of uveitis, and several medications have recently been evaluated in horses.9–13
The data pertaining to the use of IVG injections have been anecdotal, and long-term
follow-up data are presently not available.9–11 A recent retrospective case series eval-
uating the efficacy of the IVG injections for various types and stages of ERU has been
conducted and has influenced the way equine uveitis cases are managed.11 The au-
thors use a standard diagnostic protocol consisting of a complete and thorough
ophthalmic examination by a board-certified veterinary ophthalmologist, which in-
cludes examination with a slit lamp biomicroscope, indirect ophthalmoscopy, tonom-
etry, fluorescein staining of the external ocular structures, and color and infrared digital
images, at a minimum. Ocular ultrasonography and fundus photography are
performed as deemed necessary. Following examination and establishing a clinical
diagnosis, the affected horses are sedated, local eyelid blocks are performed, and
IVG 4-mg injections and aqueocentesis are performed.11 The number of recurrences
post-IVG injection is less than 15%. Therefore, the number of horses requiring surgical
intervention or intensive long-term medical management is low. The complication
rates associated with the injections are also low, but do consist of mature cataract for-
mation/progression (5 out of 59 eyes; 8.5%) and/or retinal degeneration (3 out of 5
eyes; 5.1%).11 Additional research and more long-term follow-up from a large number
of treated horses will help to determine the true prevalence.11
Because aqueous paracentesis and IVG injections are performed under sedation, all
risks associated with general anesthesia can be avoided, unless a horse requires
Table 5
Systemic medications for equine recurrent uveitis
Drug Class Medications Frequency Pros Cons
NSAIDs Flunixin meglumine
(0.25–1.1 mg/kg
IV, PO)
q 12–24 h Potent and
effective:
ophthalmic
disease
Chronic use may
lead to gastric and
renal toxicity
Phenylbutazone
(2.2–4.4 mg/kg
IV, PO)
q 12–24 h Moderately potent:
ophthalmic
disease
Chronic use may
lead to gastric and
renal toxicity
Less effective than
flunixin
meglumine
Corticosteroids Dexamethasone
(6–10 mg/500 kg,
PO or 2.6–6 mg/
500 kg, IM)
q 24 h Potent
antiinflammatory
Use with caution
and monitor for
laminitis
Prednisolone
(100–300 mg/
500 kg, IM, PO)
q 24 h Potent
antiinflammatory
Use with caution
and monitor for
laminitis
Abbreviations: IM, intramuscular; IV, intravenous; NSAIDs, nonsteroidal antiinflammatory drugs;
PO, by mouth.
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additional treatment because it has not responded to the initial IVG injection, and sur-
gical placement of a cyclosporine implant or pars plana vitrectomy are deemed neces-
sary.15–19 This logical step-by-step approach has reduced the number of horses
requiring surgery, while simultaneously decreasing the number of recurrent bouts of
inflammation in our study population.11 Anecdotally, it is common to inject gentamicin
and triamcinolone intravitreally as a combination, but we have refrained from doing so
in order to gain an appreciation of the efficacy of gentamicin in controlling ERU and
preventing recurrent bouts of inflammation, as well as to minimize/eliminate the com-
plications that may occur when using intravitreal corticosteroids. Within our study
population, the use of triamcinolone acetonide has not been deemed necessary
(Table 6).11
Another promising technique is the injection of triamcinolone acetonide into the
suprachoroidal space.14 This technique requires specially machined microneedles
to perform, and potentially eliminates the secondary complications (corneal ulcera-
tion, secondary infection, corneal mineralization [Fig. 14], and endophthalmitis) asso-
ciated with intravitreal triamcinolone injections.13
SURGICAL TREATMENT OPTIONS
There are currently 2 surgical options to treat ERU: suprachoroidal placement of
sustained-release cyclosporine devices and dual-port pars plana vitrectomy.15–19 It
is commonly inferred that ERU in Europe is different from ERU seen in the United
States.1–4 Although there are geographic and breed-related differences that are
more pronounced on either side of the Atlantic Ocean, there are more similarities
than is generally supposed.31,32
Table 6
Medications for intravitreal and suprachoroidal space injections for equine recurrent uveitis
Route of
Administration Medications Frequency Pros Cons
Intravitreal
injection
Gentamicin
(4 mg,
preservative
free)
Once Potential to
interrupt and stop
recurrent bouts of
inflammation
Mechanism of action
unknown
May cause cataract
formation/
maturation or
retinal
degeneration
Triamcinolone
acetonide
(2.5–5.0 mg)
As necessary
based on
clinical
response
Duration of action,
4–9 mo (monitor
intravitreal
crystals)
Markedly increased
risk of secondary
infections (fungal
or bacterial) and
corneal
degeneration
Cannot be removed
once administered
Suprachoroidal
space injection
Triamcinolone
acetonide
(5.0 mg)
As necessary
based on
clinical
response
Corneal drug
concentration
eliminated:
drastically
reduced risk of
secondary
infection
Special needles
required (not
commercially
available)
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Some of the misconceptions about ERU are linked to the simultaneous develop-
ment of the pars plana vitrectomy17–19 and intravitreal and subsequently suprachoroi-
dal cyclosporine implants15,33,34 in Germany and North Carolina, respectively. There is
a greater population of Appaloosa and western sport horses in the United States
compared with Germany’s more dominant warmblood population. Coupled with the
different examination techniques routinely used in each country, this accounts for
some of the misconceptions. The many types and stages of ERU can be seen in
both Europe and the United States, just at variable frequencies.
Suprachoroidal Cyclosporine Implants
Horses with documented recurrent bouts of inflammation that are well controlled with
conventional medical therapy (eg, topical and systemic antiinflammatory medication
effectively leading to a period of quiescence that remains even after medications
are discontinued) are excellent candidates for suprachoroidal cyclosporine
implantation.33,34
Inflammation can be well controlled and recurrences all but eliminated following
placement of suprachoroidal cyclosporine implants.34
Pars Plana Vitrectomy
The pars plana vitrectomy, both single port and dual port, has been well described,
and has seen widespread use, especially in Europe.17–19,29,35 It is an intraocular pro-
cedure that is used primarily to remove the core of the vitreous with the horse under
general anesthesia. The procedure is not routinely performed under an operating mi-
croscope and direct visualization of the vitrector (cutting instrument) is achieved using
an indirect ophthalmoscope. Without the use of a condensing lens there is limited
depth perception and extreme care must be taken not to inadvertently damage the
posterior lens or retina. Although the procedure has seen widespread use in Europe,
there are few studies evaluating the long-term surgical results following vitrec-
tomy.19,29,36 Reported postsurgical complications include transient hypopyon, vitreal
and/or retinal hemorrhage, retinal detachment, and cataract formation.1,19 Horses
with Leptospira-associated uveitis (C-value >4), and moderate to severe vitreal inflam-
mation (membranes) are considered good surgical candidates.29
Fig. 14. (A) Diffuse corneal mineralization associated with intravitreal triamcinolone aceto-
nide injection. This type of corneal mineralization is often anecdotally associated with the
chronic use of topical corticosteroids (especially dexamethasone) as well. (B) Using oblique
(or tangential) lighting as the sole source of illumination, the corneal mineralization of the
cornea from (A) can be highlighted for better visualization.
McMullen Jr & Fischer
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EVALUATION OF OUTCOME AND LONG-TERM RECOMMENDATIONS
Conservative medical management is, and should be, the first line of treatment to stop
active uveitis and to slow down or prevent recurrent bouts of inflammation. Once a
horse has been diagnosed with ERU, it requires diligent and lifelong monitoring and
care and the owners should be prepared for this.8 If recurrences occur despite appro-
priate medical therapy,6–8 then additional treatment modalities should be considered.
In these situations, intravitreal and suprachoroidal injections provide an effective
alternative to surgery, and can be performed under sedation, at the same time as diag-
nostic aqueous paracentesis.11–14,29 If the horse does not respond favorably to con-
servative medical or injection therapy, the best surgical option for each individual
horse can be made based on the clinical signs that are still present, the anatomic diag-
nosis, and the laboratory results.1,11,29,35
SUMMARY
ERU is a complex and challenging disease, but clinicians are currently in a position to
improve the long-term results with early intervention, making a proper diagnosis, and
selecting the most appropriate treatment option for the individual horse. The reality is
that more horses will go blind or experience debilitating ocular damage long term with
medical therapy alone than with any other form of intervention.1,7,8 Although the risks
associated with the various injections and surgical options (cataract formation, retinal
degeneration, retinal detachment, intraocular hemorrhage) remain present, the likeli-
hood of their occurring can be dramatically reduced.10,11,16,19,29,36
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4 DISCUSSION 
Useful diagnostic information pertaining to the ocular Leptospira status can be 
obtained by performing aqueous paracentesis at the time of IVGI. The information 
obtained  is valuable, especially in cases where the inflammation cannot be controlled 
by IVGI. In such instances the indication for PPV or CSI can be readily made 
(TÖMÖRDY et al. 2010). When assessing the Leptospira status of the eye, it is 
imperative to compare the aqueous humor antibody titers to the serum antibody titers 
to determine if there is active intraocular antibody production (GOLDMANN and 
WITMER 2010,GILGER 2010). Failing to evaluate both the aqueous humor and serum 
antibody titers when evaluating the ocular Leptospira status, can be very misleading, 
as previous studies have shown that the serum antibody titer and the aqueous humor 
antibody titer are not correlated (FABER et al. 2000, MALALANA et al. 2017). Using 
PCR as the sole method to assess the Leptospira status of the eye, may also lead to 
misinformation, as nearly half of the uveitis cases associated with Leptospira would 
have been missed by relying only on PCR in one study (DE GROOT-MIJNES et al. 
2006).  
It is challenging to accurately categorize clinical uveitis cases by using the three 
historical categorizations classic ERU, insidious ERU and posterior ERU (GILGER and 
MICHAU 2004). There is definitely a need for a more modern and accurate 
categorization. Using the categorization of panuveitis, panuveitis with predominant 
anterior involvement, panuveitis with predominant posterior involvement, anterior 
uveitis, posterior uveitis and heterochromic iridocyclitis was an attempt to find a more 
precise way to categorize the different clinical presentations of uveitis (FISCHER et al. 
2019). As a variety of clinical signs and even the recurrent nature of the disease, can 
also be found in other ocular diseases, such as IMMK, it is challenging to accurately 
make a correct diagnosis (REBHUN 1979, GILGER 2010). Future research should 
concentrate on categorizing uveitis based on clinical signs associated with uveitis and 
correlating them with clinical manifestations of the disease in order to identify reliable 
patterns of signs, associated with different clinical manifestations of uveitis.  
The success rate of IVGI in our study was 88.1%, with vision threatening post-injection 
complications being identified in 8.5% (cataract maturation/formation) and 5.1% 
(retinal degeneration) of the cases, suggesting that IVGI may be a reliable treatment 
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option for horses presenting with various types and stages of uveitis. An additional 
benefit of IVGI is that it can be performed under sedation using minimal regional and 
topical anesthesia at the same time that aqueous humor is collected for diagnostic 
purposes (FISCHER et al. 2019). As a result, all risks associated with general 
anesthesia are consistently avoided. Being able to provide a minimally invasive 
method that can be performed under sedation may also be useful in non-visual and 
painful eyes, where owners are more reluctant to invest time, effort, and money 
towards a more expensive surgical procedure (PPV, CSI or even enucleation). 
Phthisical globes that are still actively inflamed may also benefit from IVGI (DEEG et 
al. 2007).   
Presently, the mechanism of action of gentamicin on the disease process in ERU and 
other types of equine uveitis remains enigmatic. We can only speculate as to how 
gentamicin influences this autoimmune process. Positive suppression of inflammation 
in a variety of types and stages of equine uveitis was achieved following IVGI in the 
present study, despite the Leptospira status of the eye. A recent experimental study 
discovered that suppression of dihydroorotate dehydrogenase (DHODH), which plays 
a key role in the activation of lymphocytes, is capable of almost complete inhibition of 
experimentally-induced uveitis in rats (DIEDRICHS-MOHRING et al. 2015). Targeted 
suppression of de novo pyrimidine synthesis, requiring DHODH for the activation of 
lymphocytes is achieved by feeding PP-001, a third- generation molecule to rats with 
uveitis.  Although purely speculative, the underlying mechanism of gentamicin may 
specifically, or unspecifically, block or suppress the activation of specific T-cell lines; 
cells that are known to play a significant role in autoimmune uveitis (ROMEIKE et al. 
1998). Future research to uncover the ability of gentamicin to disrupt the inflammatory 
process is warranted and necessary. 
Eyes with ERU from Appaloosas were temporarily controlled, but they all eventually 
went on to develop recurrent inflammation. Because ERU in Appaloosas tends to 
respond very differently than that seen in most other horses breeds to a variety of 
treatments (both medical and surgical), they should be monitored very closely for 
recurrences or relapses, despite appearing “normal” to their owners. Repeating IVGI 
in cases that do not respond to the initial IVGI may be an option, however, the 
cumulative effects of intraocular gentamicin will need to be determined prior to making 
any such recommendations. Additionally, 2/3 eyes from Appaloosas in the present 
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study were also diagnosed with IMMK in addition to uveitis. In general, most horses in 
the present study demonstrating unspecific recurrent ocular inflammation following 
IVGI presented with clinical manifestations of subclinical keratitis or secondary 
glaucoma, rather than recurrent uveitis. Therefore, it is important to carefully evaluate 
each horse presenting with suspected ‘recurrent uveitis’ for signs of these underlying 
diseases to ensure that a correct diagnosis is made, thus increasing the likelihood of 
a positive long-term outcome. 
Eyes presenting with glaucoma concomitant to uveitis remained free of long-term-
complications (cataracts or retinal degeneration). And, with the exception of one eye, 
all had positive clinical outcomes in terms of the uveitis remaining controlled. 
Nevertheless, glaucoma was not resolved following IVG. It has been previously 
reported that eyes with concomitant glaucoma and uveitis are more likely to be 
enucleated (GERDING and GILGER 2016). Presently, due to the poor short-term 
prognosis associated with these cases, several owners of horses affected with both 
glaucoma and uveitis ultimately elected to have these eyes enucleated. Since IVG 
offers an effective and minimally invasive means of controlling both acute and chronic 
uveitis, it’s role in the management of horses suffering from concomitant uveitis and 
secondary glaucoma should continue to be investigated.  
The present study reports a positive outcome in 88.1% (non-recurrence/ non-
persistence rate) of the eyes treated. These results substantiate the anecdotal findings 
reported by PINARD (2005) with a positive outcome of 94.4%, and those reported by 
KLEINPETER et al. (2019) showing a positive outcome in 91.8%.  
Suprachoroidal triamcinolone injections present a promising method, with minimal side 
effects, of temporarily controlling ERU (GILGER et al. 2013, GILGER 2016).  Based 
on the duration of effect (3-4 weeks), suprachoroidal triamcinolone acetonide may be 
an effective means of controlling active uveitis prior to or following other medical or 
surgical interventions (GILGER 2016). Horses receiving suprachoroidal injections of 
TA should be monitored closely for recurrent signs of uveitis, especially during the 
time-frame when the effects of the drug are expected to wane. Currently, the micro 
needles necessary to perform suprachoroidal injections in horses are not commercially 
available (MCMULLEN et al.2017).  
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The main goals in treating ERU are the reduction of ocular inflammation, the reduction 
or elimination of pain or discomfort, and the preservation of vision (GERDING and 
GILGER 2016, ALLBAUGH 2017). Medical therapy alone leads to significant vision 
loss due to the lack of long-term control of inflammation. Every bout of inflammation 
leads to more damage to the ocular structures and will ultimately lead to blindness 
(GERDING et al.2016). The introduction of the surgical techniques, PPV ad SCI, have 
improved these results, but only in cases where the indication for surgery is correct 
(WINTERBERG et al.1997, GILGER et al. 2010, TÖMÖRDYet al. 2010). PPV is 
indicated in cases with positive Leptospira C-values, whereas CSI is only effective at 
suppressing inflammation in horses that respond to immunosuppressive treatment 
(TÖMÖRDYet al. 2010, GILGER et al. 2010). It is therefore essential to have an 
accurate diagnosis and prior response to therapy in order to select the appropriate 
treatment approach. According to a recent study by FISCHER et al. (2019), IVGI is 
able to control inflammation despite the Leptospira status of the eye and despite the 
response to immuosuppressive treatment. Compared with published results following 
cyclosporine implant placement (46% non-recurrence rate, 16% cataract 
progression/formation and 16% retinal degeneration) and pars plana vitrectomy 
(73.6% - 100% non-recurrence rate, 38.2% - 44.2% cataract progression/formation, 
and 9.3% retinal degeneration) the complication rates associated with IVG injections 
(88.1% non-recurrence rate/non-persistance rate, 8.5% cataract 
progression/maturation, and 5.1% retinal degeneration) are low (WERRY and 
GERHARDS 1954, WINTERBERG and GERHARDS 1997,  FRÜHAUF et al. 1998,  
VON BORSTEL et al. 2005, TÖMÖRDY et al. 2010, GILGER et al. 2010). This makes 
IVGI an excellent treatment option.  
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5 ZUSAMMENFASSUNG 
Britta Maria Fischer 
Intravitreale Injektion von niedrig dosiertem Gentamicin: eine alternative 
Methode zur Behandlung der equinen rezidivierenden Uveitis 
KLINIK FÜR PFERDE DER VETERINÄRMEDIZINISCHEN FAKULTÄT DER 
UNIVERSITÄT LEIPZIG 
Eingereicht im Mai 2020 
(52 Seiten, 18 Abbildungen, 13 Tabellen, 110 Literaturangaben)
Schlüsselwörter: Equine recurrent uveitis - intravitreale Injektion- Gentamicin – 
Leptospiren - Pferde Augenheilkunde 
Zielstellung: Ziel der Arbeit war es, die Technik der intravitrealen Gentamicin Injektion 
darzulegen, die Auswirkungen dieser auf die klinischen Symptome von Uveitiden, 
sowie die möglichen  unmittelbaren Komplikationen (innerhalb von 24 Stunden) und 
längerfristigen Komplikationen (30 bis 780 Tage) die mit dieser Technik verbunden 
sein können, zu beschreiben. Zusätzlich wurde der okuläre und systemische 
Leptospiren- Status ermittelt und der Einfluss dieser auf das Behandlungsergebnis 
untersucht. 
Material und Methode: 86 Pferde verschiedenen Alters, Rasse und Geschlechts, mit 
wiederkehrender oder persistierender Uveitis, wurden mit 4mg einer unverdünnten 
Gentamicininjektion (0,04 ml, Genta 100, 100 mg/ml bei 35 Pferden) oder einer 
Konservierungsstoff freien Gentamicin Injektion (0,05 ml, 80 mg/ml bei 52 Pferden) 
unter Sedation und lokaler Anästhesie behandelt. 
Ergebnisse: Subkonjunktivale Blutungen (26/86; 30,2 %) und intrakamerale 
Blutungen (4/86; 4,7 %) zählten zu den unmittelbaren Komplikationen. Die 
Komplikationen nach der Injektion bestanden aus Kataraktbildung oder -reifung 
(5/59 Augen; 8,5 %) und Netzhautdegeneration (3/59 Augen; 5,1 %). Bei der 
Mehrzahl der Pferde war ein positiver Therapieerfolg (keine weiteren 
rezidivierenden oder persistierenden Entzündungen) zu beobachten (52/59 
Pferde; 88,1 %). Wiederkehrende Entzündungen wurden in 5/59 (8,5 %) 
Pferden und persistierende Entzündung in 2/59 (3,4 %) Pferden beobachtet.  
Schlussfolgerungen: Die niedrig-dosierte intravitreale Gentamicin Injektion stellt eine 
vielversprechende Behandlungsmethode für verschiedene Typen und Grade von 
Uveitiden dar. Der relativ hohe Prozentsatz an positivem Behandlungserfolg 
verbunden mit nur geringen Komplikationsraten rechtfertigt weitere Untersuchungen. 
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6 SUMMARY 
Britta Maria Fischer 
Intravitreal injection of low-dose gentamicin: an alternative method of 
management for equine recurrent uveitis  
DEPARTMENT FOR HORSES, FACULTY OF VETERINARY MEDICINE, 
UNIVERSITY OF LEIPZIG 
Submitted in May 2020 
(52 pages, 18 figures, 13 tables, 110 references)
Keywords: Equine recurrent uveitis – intravitreal injection – Gentamicin – Leptospira – 
Equine ophthalmology 
Objective: To describe the intravitreal gentamicin injection technique, report the effects 
of the injection on the clinical signs of uveitis and to describe the associated peri-
injection (within 24 hours) and post-injection complications (30 to 780 days). 
Additionally, evaluation of the systemic and ocular Leptospira status and its effects on 
the treatment outcome was performed.  
Material and Methods: 86 horses of various ages, breeds, and gender presenting with 
recurrent or persistent uveitis were treated via intravitreal injection of 4 mg of undiluted 
gentamicin (0.04 ml, Genta 100, 100mg/ml in 35 horses) or preservative-free 
gentamicin (0.05 ml, 80mg/ml in 52 horses) under sedation and local anesthesia. All 
86 horses were observed for complications, and 59 horses were evaluated for their 
response to therapy (follow-up: 30 to 780 days).  
Results: Peri-injection complications consisted of subconjunctival (26/86; 30.2%) or 
intracameral hemorrhage (4/86; 4.7%). Post-injection complications consisted of 
cataract formation/maturation (5/59 horses, 8.5%) and retinal degeneration (3/59 eyes 
5.1%). The majority of horses 52/59 (88.1%) had a positive clinical outcome (absence 
of recurrent or persistent inflammation). Recurrent inflammation was documented in 
5/59 (8.5%) horses and persistent inflammation was diagnosed in 2/59 (3.4%) horses. 
Conclusion: Intravitreal injection of low-dose gentamicin shows promise at controlling 
different types and stages of uveitis. The relatively high rate of success and low 
complication rate warrants further investigation.  
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